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Abstract: During the last decade there has been a growing interest in glycoimmunology, a relatively
new research field dealing with the specific interactions of carbohydrates with the immune system.
Pathogens’ cell surfaces are covered by a thick layer of oligo- and polysaccharides that are crucial
virulence factors, as they mediate receptors binding on host cells for initial adhesion and organism
invasion. Since in most cases these saccharide structures are uniquely exposed on the pathogen
surface, they represent attractive targets for vaccine design. Polysaccharides isolated from cell walls
of microorganisms and chemically conjugated to immunogenic proteins have been used as antigens
for vaccine development for a range of infectious diseases. However, several challenges are associated
with carbohydrate antigens purified from natural sources, such as their difficult characterization and
heterogeneous composition. Consequently, glycoconjugates with chemically well-defined structures,
that are able to confer highly reproducible biological properties and a better safety profile, are at
the forefront of vaccine development. Following on from our previous review on the subject, in the
present account we specifically focus on the most recent advances in the synthesis and preliminary
immunological evaluation of next generation glycoconjugate vaccines designed to target bacterial
and fungal infections that have been reported in the literature since 2011.
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1. Introduction
Notwithstanding the great advances of modern medicine, infectious diseases still have a strong
impact on public health, both in industrialized and developing countries, due to their significant
health-related costs for clinical treatment. In particular, the list of the drug-resistant bacteria is
increasing continuously, and novel and more efficient means to prevent microbial infections caused by
antibiotic-resistant microorganisms are urgently needed. According to the World Health Organization
(WHO) [1], vaccination is the most cost-effective strategy for controlling infections caused by
pathogenic microorganisms. Actually, vaccines are able to confer long-term protective immunity
on the population and have made possible a great revolution in the 20th century, saving millions
of lives.
The surface of bacterial pathogens is covered with a dense array of complex glycans, such as
lipopolysaccharide of Gram-negative bacteria and the polysaccharide coat (capsular polysaccharides,
CPS) of encapsulated bacteria that are crucial protective antigens and major virulence factors.
For example, each strain of Streptococcus pneumoniae (the pneumococcus) produces one out of
90 different capsular polysaccharides, which are believed to have been selected as a mechanism
to evade the human immune response [2]. All these glycoforms are capable of interacting with the
immune system inducing the production of carbohydrate-specific antibodies. They therefore represent
attractive targets for vaccine design.
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A major drawback of polysaccharide-based vaccines, however, is their limited clinical efficacy.
They induce T cell-independent immune responses, featured by poor immunogenicity in children
under 5 years of age, in elderly and immunocompromised individuals, and fail to generate conventional
B cell-mediated immunological memory. Polysaccharide immunogenicity can be strongly enhanced by
conjugation to an immunogenic carrier protein, providing T cell-dependent glycoconjugate antigens
able to stimulate B cell maturation to memory cells and induce immunoglobulin class switching from
IgM to polysaccharide-specific IgG. The introduction of glycoconjugate vaccines represented one
of the keys for success of vaccination, especially for infants and young children who are the most
affected population by infectious diseases [3–6]. Carbohydrate-based antigens needed for inclusion
in a glycoconjugate vaccine, however, are not readily available from natural sources. In particular,
the isolation and purification of naturally occurring glycans is still a great challenge that may lead to
heterogeneous compositions and batch-to-batch variability. A relevant example is the toxic endotoxin
lipid A, a major component of the lipopolysaccharide (LPS) of Shigella flexneri 2a. The development of
LPS-based conjugate vaccines against Shigella flexneri requires careful LPS-detoxification, a technically
demanding and expensive process which also increases the manufacture costs [7,8]. Hence, the
development of cost-effective, glycoconjugate vaccines based on fully synthetic saccharide antigens
is gaining growing importance, as demonstrated by the outstanding success of the synthetic vaccine
Quimi-Hib [9]. Synthetic glycans, indeed, possess well-defined compositions, affording highly
reproducible biological properties and a better safety profile. In addition, synthetic oligosaccharides
can help to elucidate the minimal structure of the microbial polysaccharide, referred to as epitope or
antigenic determinant [10], that can ensure production of a sufficient amount of bactericidal antibodies
to confer long term protective immunity of the host. This step is crucial for the design of a new
generation of improved and safer vaccines obtained either from chemical synthesis or bacterial source.
Consequently, glycoconjugates based on chemically well-defined oligosaccharide structures are now
at the forefront of vaccine development.
Molecules 2018, 23, x FOR PEER REVIEW  2 of 52 
 
A major drawback of polysaccharide-based vaccines, however, is their limited clinical efficacy. 
They induce T cell-independent immune responses, featured by poor immunogenicity in children 
under 5 years of age, in elderly and immunocompromised individuals, and fail to generate 
conventional B cell-mediated immunological memory. Polysaccharide immunogenicity can be 
strongly enhanced by conjug tion to an immunogenic carrier protein, providing T cell-dependent 
glycoconjugate antigens able to stimulate B cell maturation to memory cells and induce 
immunoglobulin class switching from IgM to polysaccharide-specific IgG. The introduction of 
glycoconjugate vaccines represented one of the keys for success of vaccination, especially for infants 
and young children who are the most affected population by infectious diseases [3–6]. Carbohydrate-
based antigens needed for inclusion in a glycoconjugate vaccine, however, are not readily available 
from natural sourc s. In particular, the i olation and purification of naturally occurring glycans is 
still a great challenge that may lead to heterogeneous compositions and batch-to-batch variability. A 
relevant example is the toxic endotoxin lipid A, a major component of the lipopolysaccharide (LPS) 
of Shigella flexneri 2a. The development of LPS-based conjugate vaccines against Shigella flexneri 
requires careful LPS-detoxification, a technically demanding and expensive process which also 
increases the anufactur  costs [7,8]. Henc , the development of co t-effective, glycoco jugate 
vaccines based on full  synthetic saccharide antigens is gaining growing importance, as 
demonstrated by the outstanding success of the synthetic vaccine Quimi-Hib [9]. Synthetic glycans, 
indeed, possess well-defined compositions, affording highly reproducible biological properties and 
a better safety profile. In addition, synthetic oligosaccharides can help to elucidate the minimal 
structure of the microbial polysaccharide, referred to as epitope or antigenic determinant [10], that 
can ensur  production of a sufficient amount of bactericidal antibodies to confer ong term protective 
immunity of the host. This step is crucial for the esign of a new generation of improved and safer 
vaccines obtained either from chemical synthesis or bacterial source. Consequently, glycoconjugates 
based on chemically well-defined oligosaccharide structures are now at the forefront of vaccine 
development. 
 
Figure 1. Representation of the monosaccharide building blocks contained in the glycans of pathogen 
cell wall PS accounted in this manuscript. 
f
f
Figure 1. Representation of the monosaccharide building blocks contained in the glycans of pathogen
cell wall PS accounted in this manuscript.
Over the last years, the synthesis of complex glycans has made significant progress. A variety
of synthetic approaches such as automated solid phase synthesis, one-pot programmable synthesis,
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enzymatic and improved synthetic methods have introduced new and elegant ways to provide
oligosaccharide antigens with well-defined chemical structure for immunological studies. Meanwhile,
improved methods for structural elucidation, based on X-ray crystallography, NMR, or in silico
studies, as well as advanced techniques to study carbohydrate-protein interactions (glycoarray, surface
plasmon resonance, isothermal titration calorimetry, competitive ELISA assay) have been extensively
applied to predict the minimal structural requirements needed for the immunological activity of the
oligosaccharides. Accordingly, a variety of saccharide fragments reproducing or mimicking the surface
carbohydrates of pathogens have been synthesized, coupled to carrier proteins or T cell peptides, and
tested for their ability to elicit protective antibodies in animal models. In this regard, in the present
review we focus on the most significant advances in the synthesis and preliminary immunological
evaluation of synthetic antibacterial and antifungal glycoconjugate vaccine candidates, appeared in
the literature from 2011 onwards, following our previous account on the subject [11]. For clarity,
the diagrammatic representations of the monosaccharide residues [12] illustrated in Figure 1 above are
used throughout this review.
2. Shigella
The Shigella family includes four different groups of Gram-negative bacteria—S. dysenteriae,
S. sonnei, S. flexneri and S. boydii—each of them comprising different serotypes. Shigella is the
causative agent of endemic and epidemic shigellosis or bacillary dysentery, an invasive disease
of the lower intestine, highly diffused in developing countries and particularly in pediatric population.
The development of a fully synthetic glycoconjugate vaccine against S. dysenteriae type 1 is currently
under investigation, using fragments of the O-antigen of the Shigella LPS. Oligomers up to four
repeating units of the tetrasaccharide [α-L-Rha-(1→2)-α-D-Gal-(1→3)-α-D-GlcNAc-(1→3)-α-L-Rha]
were first synthesized by Pozsgay and covalently linked to human serum albumin (HSA) [13,14].
Preliminary studies showed that the hexadecasaccharide (n = 4) is the most immunogenic fragment
able to elicit anti O-SP-specific IgG in mice [14] and that the upstream residue (non-reducing end) of
the synthetic fragments is crucial for the immunogenicity of these conjugates [15].
S. flexneri serotype 2a is the most prevalent pathogenic strain in human and a major cause of the
endemic form of shigellosis in developing countries. The O-antigen of S. flexneri 2a surface LPS is an
essential virulence factor and consists of a branched pentasaccharide repeating unit (Figure 2).
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In 2005, the Mulard group reported the synthesis of the monomer, dimer and trimer of the
pentasaccharide repeating unit (AB(E)CD, Figure 2) and their conjugation to a universal T cell peptide
epitope, the pan HLA DR-binding epitope (PADRE) [16,17]. Subsequently, the synthesis of S. flexneri
serotype 2a O-Ag synthetic fragments 1a–18a (Figure 2) was reported [19]. The antigenicity of all
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synthetic fragments 1a–18a was evaluated by ELISA assays, in order to identify the immunogenic
determinants recognized by five protective mIgGs specific to serotype 2a O-Ag. None of the mono- or
disaccharides was recognized, while the sequence ECD (trisaccharide 9a) was the only one recognized
by one mIgG out of five. Tetrasaccharide B(E)CD 13a was recognized by three of the protective mIgG
out of five. The minimal sequences for recognition of all mIgGs were pentasaccharides AB(E)CD 16a
and B(E)CDA 14a. Following these encouraging results, some selected synthetic oligosaccharides
were conjugated to tetanus toxoid (TT) protein and used for immunization studies in mice, leading to
the identification of a hit glycoconjugate, 19b, containing the trimer of the pentasaccharide AB(E)CD.
Glycoconjugate 19b induced an efficient serotype 2a-specific anti-O-Ag Ab response and it was found
to be a functional mimic of the native polysaccharide [20]. Recently, Mulard et al. established a
reproducible bioconjugation method for the synthesis of the pentadecasaccharide−TT conjugate 19b,
which allowed complete control of the optimal loading [18]. Alum, an adjuvant used in licensed
glycoconjugate vaccines like Prevnar 13 or Synflorix, was added to S. flexneri serotype 2a vaccine
candidate 19b, which upon immunization was shown to generate a higher and sustained anti-LPS IgG
response compared to their nonadjuvanted form [18]. Importantly, Mulard et al. showed that anti-LPS
IgG elicited by their synthetic TT conjugate 19b recognized SF2a bacteria and not only purified SF2a
LPS [18]. In addition to these promising findings, the influence of O-acetylation of S. flexneri 2a O-Ag
fragments on antigenicity was studied by Mulard group [21]. Polysaccharide O-acetylation has been
shown to play a key role for many pathogens in inducing functional Ab responses [22–24]. In particular,
three diversely O-acetylated S. flexneri 2a O-Ag decasaccharides were synthesized in homogeneous
form and their binding to five different protective mAbs was studied, showing some differences in
the recognition patterns. Although these data couldn’t provide an exhaustive proof of the role of
O-acetylation for S. flexneri 2a O-Ag and of the effect of multiple acetates on the antigen, this work
showed that studies using synthetic oligosaccharides may contribute to a better understanding of the
antigen-antibody molecular recognition event.
3. Clostridium difficile
Clostridium difficile is a Gram-positive, spore-forming anaerobic bacterium causing
Clostridium difficile infection (CDI), a serious diarrhoeal disease and one of the major cause of
hospital-acquired infections (also known as nosocomial infections) in Western countries [25].
The epidemiology of CDI has changed dramatically during this millennium, especially in relation
to its clinical presentation, response to treatment and antibiotic resistance [25,26]. In general, after
antibiotic treatment that leads to the disruption of the gut microbiota, the intestinal epithelium
could be colonized by antibiotic-resistant C. difficile spores, which secrete two toxins (toxin A and
toxin B) responsible for the clinical symptoms of CDI. Immune-based strategies based on passive
administration of monoclonal antibodies against C. difficile toxins and surface proteins to treat or
prevent CDI in animal models and in clinical trials have been recently reviewed [27,28]. Concurrently,
bacterial surface glycans, such as PS-I and PS-II, have been recently proposed as potential target for
vaccine development with the aim of preventing bacterial adhesion and colonization.
3.1. PS-I-Clostridium difficile
Recently, Martin et al. reported the synthesis of the pentasaccharide repeating unit of PS-I cell wall
polysaccharide of C. difficile ribotype 027 (Figure 3), of its related substructures (compounds 20a–25a,
Figure 3) and their immunological evaluation for the identification of the minimal epitope [29].
The synthetic fragments were synthesized from monosaccharide building blocks 26–30, linearly
proceeding from the downstream end to the upstream end. In particular, the use of the non
participating benzyl group at C-2 of thioglycoside 29 provided the condition for 1,2-cis stereoselective
glycosylation of glucoside 30, bearing the linker at the anomeric position. Thioglycoside 29 was
functionalized with the orthogonal protecting groups para-bromobenzyl (PBB) ether at C-3 and
levulinoyl (Lev) ester at C-4 for installation of the branching point.
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Glycans 20a–25a, immobilized on microarrays, were screened for antibody recognition with
samples from C. difficile patients (stools for IgA and serum for IgG). IgA and IgG antibodies
specific to all glycan antigens were present in most fecal samples and sera, respectively, of both
patients and control groups. Reconvalescent patients showed highly variable antibody levels
and statistically higher IgG levels. Pentasaccharide 25a was conjugated to CRM197 (non-toxic
mutant of diphtheria toxin) and the resulting glycoconjugate 25b was injected in mice, inducing
Ig class switching, affinity maturati n and producing self-specific antib dies, without eliciting
antibodies against two control oligosaccharides (C. difficile PS-II hexasacchar de and Leishmania
lipophosphoglycan capping t trasaccharide). Interestingly, antibodies raised by glycoconjugate 25b
also recognized trisaccharide 22a and disaccharide α-Rha-(1→3)-Glc 21a, which was identified as the
minimal epitope. Indeed, α-Rha-(1→3)-Glc disaccharide-CRM197 conjugate 21b was able to induce
antibodies recognizing the C. difficile PS-I pentasaccharide 25a. In a following work [30], a multivalent
presentation of disaccharide 21a on an oligo(amidoamine) synthetic scaffold [31] was shown to be
highly antigenic. In particular, a pentavalent presentation of the disaccharide 31 (Figure 3), built on
the oligo(amidoamine) backbone and displaying a T-cell epitope (amino acids 366–383 of the CRM197
protein) showed increased antigenicity compared with monovalent 21b, eliciting antibodies against
pentasaccharide 25a. A de ailed investigation of the glycan-a tibody binding was conducted with a
combination of different techniques lik glycan microarray, surface plasmon resonance, interaction
map, saturation transfer difference (STD)-NMR and isothermal titration calorimetry (ITC). It was
demonstrated that the mAbs mainly interacted with the terminal rhamnose and the adjacent glucose
of the disaccharide 21a and that in pentasaccharide 25a the linkage connecting the two disaccharides
is not directly engaged in antibody binding, although the affinity (KD) increases from micromolar
for disaccharide 21a to nanomolar for pentasaccharide 25a. Both glycoconjugates 21b and 25b are
currently in preclinical evaluation as novel vaccine candidates against C. difficile.
3.2. PS-II-Clostridium difficile
The chemical synthesis of the hexasaccharide repeating unit (Figure 4) of PS-II cell wall
polysaccharide of C. difficile ribotype 027, one of the most virulent strains, with two similar synthetic
strategies, was reported simultaneously by two groups in 2011 [32,33].
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The synthesis f PS-II oligosaccharide lacking the phosphate group (compound 32a, Figure 4) was
carried out by Oberli et al. [32] via a [4+2] glycosylation of tetrasaccharide AB(D)C 33 with disaccharide
B’C’ 34, starting from monosaccharide building blocks 35–38. Hexasaccharide conjugated to CRM197
(32b) was used for mice immunization and resulted in the production of IgG antibodies that bound
specifically hapten 32a. In addition, IgA antibodies from the stools of patients diagnosed with CDI
(the supernatant stools, and not the serum, were chosen becau e the contact site with C. difficile is
the intestinal mucosa) were analyzed. Glycan microarrays containing hexasaccharide antigen 32a
were used to screen patient samples. Anti-PS-II IgA antibodies were found in the stools of patients
diagnosed with CDI, suggesting that the synthetic hexasaccharide could be used in a glycoconjugate
vaccine candidate against CDI.
Danieli et al. [33] reported the synthesis of hexasaccharide 39a and its phosphorylated analogue
40a, starting from disaccharide 41 and tetrasaccharide 42 (or its a alogue 43) via a [4+2] convergent
approach (Figure 5).
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Tetrasaccharide 42 was in turn prepared from monosaccharide building blocks 44–47, by first
assembling the linear trisaccharide ABC and then inserting the α-Glc D unit [33]. An alternative route
leading to tetrasaccharide 43 starting from building blocks 48, 49 and 50 was also developed [34].
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Of note, the glycosylation with 4,6-O-benzylidene-protected ethylthioglycoside 47 allowed the
stereoselective introduction of the 1,2-cis linkage for both routes. Tetrasaccharide AB(D)C 51a,
obtained from deprotection of 43, was also synthesized to examine the effect of the branching point
of the hexaglycosyl unit in determining the immunogenicity. Sera from mice immunized with the
PSII-CRM197 conjugate were used to check their capability to bind synthetic fragments 39a, 40a, 51a.
Tetrasaccharide 51a showed no binding, while both 39a and phosphorylated fragment 40a bound
anti-PSII antibodies. In a second experiment, the three synthetic glycans conjugated to CRM197
(compounds 39b, 40b and 51b) and native PSII-CRM197 were injected in mice and evaluated for
their ability to elicit anti PSII antibodies. Sera were analyzed by ELISA for their content of anti PSII
IgG, using PSII-HSA for the coating of the plates. Interestingly, only the glycoconjugates obtained
from the native polysaccharide and the phosphorylated hexasaccharide 40b were able to induce IgG
antibodies that bound PSII and low levels of anti-PSII IgM antibodies. Tetrasaccharide 51b and the
nonphosphorylated hexasaccharide 39b elicited self-specific antibodies but did not induce IgG nor IgM
anti-PSII titers. A comparison between the studies of Oberli et al. [32] and Adamo et al. [34] reveals that
the phosphate group on the hexasaccharide repeating unit of PS-II plays a subtle immunological role.
Indeed, the phosphate group is not required to raise IgG antibodies production against hexasaccharide
hapten 32a, while it is a prerequisite to elicit antibodies recognizing, besides the phosphorylated and
the nonphosporylated hapten, also the native PS-II polysaccharide. These findings suggested that
the charged phosphate is crucial to mimic the native PSII polysaccharide [34] and can be used for the
design of carbohydrate antigens as vaccine candidates.
4. Burkholderia pseudomallei
Burkholderia pseudomallei is a Gram-negative environmental bacterium which is widespread in the
soil and surface water in southeast Asia and northern Australia, causing melioidosis, a serious and often
fatal disease presenting acute pulmonary infections, fulminant sepsis and chronic infection mimicking
tuberculosis [35]. Antibiotic treatment is usually divided into two phases: a first phase to prevent death
from sepsis and a second phase with the aim of preventing recurrence [36]. This protracted treatment
is not always successful and mortality rate remains high (from 15% in Australia to 40% in Thailand,
approaching 90% with septicaemia) [37]. For this reason, substantial effort has been undertaken to
develop vaccine candidates which would protect humans against B. pseudomallei infections [38]. Among
the identified virulence factors [39], the capsular polysaccharide of B. pseudomallei, a homopolymer of
2-O-acetyl manno-heptopyranose (Figure 6) has been recently considered for the development of an
effective melioidosis vaccine [40].
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Of note, B. pseudomallei CPS is expressed as a unique serotype in all reported isolates [41], identical
to the CPS of the related bacterium Burkholderia mallei [42]. The synthesis of B. pseudomallei and
B. mallei CPS is challenging due to the presence of β-mannoside linkages and of the CH2-extension
at C-6 (Figure 6). In 2016, Scott et al. [37] reported the first synthesis of hexasaccharide 52a starting
from key disaccharide fragment 53, which was in turn synthesized from disaccharide 54, which
was assembled from building blocks 55 and 56, convergently prepared in large scale from common
intermediate 57. This compound was obtained in seven steps from glycal intermediate 58, which was
synthesized from mannose 59 (Figure 6). The β-mannoside linkages were introduced using an indirect
method, based on stereoselective β-glycosylation (ensured by 2-O-acyl participation on the donor)
followed by C-2 epimerization. The latter step, leading to the manno-configuration, was performed
at the disaccharide level and after each iterative coupling, through a two-step oxidation-reduction
with high stereoselectivity. Hexasaccharide 52a was covalently linked to TT and glycoconjugate 52b,
upon mice immunization, raised low but detectable levels of IgG/IgM, as determined by ELISA test.
Glycoconjugate 52b, however, was shown to stimulate production of antibodies specific for native
CPS, with high functional activity correlated with protective efficacy, as observed by protection in mice
following a lethal dose administration of B. pseudomallei [37].
5. Brucella
Brucella is one of the world’s major zoonotic pathogens, causing brucellosis, primarily a disease
of animals, such as swine, dogs, cattle, sheep, and goats [43]. Humans are infected by close animal
contact or consumption of animal products (raw milk, raw milk products, or raw meat) infected by
bacteria of the genus [44,45]. The genus Brucella comprises Gram-negative, facultative and intracellular
pathogens and the current classification of recognized species is based on phenotypic characteristics,
antigenic variation and prevalence of infection in different animal hosts [46,47]. The disease is not
spread by human-human contact and the vaccination of animals appears as the only means for
disease eradication by vaccination strategies [48]. The O-antigen polysaccharide domain (OPS)
of Brucella LPS is a copolymer of two distinct homopolysaccharide sequences containing the rare
sugar 4,6-dideoxy-4-formamido-α-D-mannose (-α-D-Rhap4NFo) [6] and simultaneously expresses two
antigens, the A and M antigens (Figure 7).
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Three Brucella antigenic phenotypes A+M− (A-dominant), A−M+ (M-dominant) and A+M+ have
been identified in Brucella strains [50] and antibodies (IgM) against A and M antigens have been used
to detect brucellosis [51,52]. The chemical structure of A and M antigens (Figure 7) was definitively
elucidated only recently [53]: a longer inner sequence of α(1,2)-linked residues constitutes the A
antigen. A shorter sequence, the M antigen, consists of tetrasaccharide repeating units linked as
[α(1,2);α(1,3);α(1,2)] and attached to additional copies of this tetrasaccharide or to the A antigen by an
α(1,2) linkage [49].
In 2013, the Bundle group [54] reported the synthesis of pentasaccharide 60a (Figure 7) and
nonasaccharide 61a, starting from monosaccharides 62, 63 and 64. The synthetic compounds were
tested for antigenicity, after conjugation with bovine serum albumin (BSA) [54]. Glycoconjugate
60b was designed to selectively exhibit the M epitope with limited cross reactivity with A-specific
antibodies. The nonasaccharide conjugate (compound 61b), containing A and M epitopes, was
designed as a possible universal antigen to detect antibodies in animals or humans infected by
B. abortus, B. melitensis, and B. suis. An ELISA test was performed with two monoclonal antibodies
(YsT9-1 and Bm10) specific for the Brucella A and M antigens, respectively. Interestingly, nonasaccharide
antigen 61a bound A- and M-specific antibodies with equivalent avidity, whereas pentasaccharide
60a displays a preference for the M-specific antibody, as expected. However, pentasaccharide 60a,
still displaying α(1,2)-linked residues, retained modest to good binding to A-specific mAbs. This
initial result paved the way to produce a glycoconjugate vaccine that would not raise antibodies
giving false positive results in diagnostic tests for infection. Indeed, the detection of specific anti-M
antibodies would indicate infection by Brucella and not by one of the other closely related bacteria that
have PS containing 1,2-linked Rha4NFo or Rha4NAc and are known to induce antibodies reactive
in the serological test for brucellosis [55]. In a following work, tetrasaccharide 65a, disaccharide
66a and trisaccharides 67a and 68a (Figure 7) were synthesized to assess the largest and smallest M
epitopes [56]. International standard B. abortus serum prepared from cattle experimentally infected with
an A-dominant strain bound strongly to disaccharide-BSA conjugate 66b and M tetrasaccharide-BSA
conjugate 65b [56]. In addition, 65b and 66b also showed strong binding to M-specific mAbs and
weak binding with A-specific mAbs. It was also observed that antibodies raised against exclusively
α(1,2)-linked Rhap4NFo did not bind well to the 1,3-linked disaccharide [57]. Further improvement
of serodiagnosis of brucellosis came when a tether was introduced at the O-4 of the upstream
residue (heptasaccharide 69a, Figure 7) [58]. In particular, conjugate 69b (TT) was used for mice
immunization and conjugate 68c (with bovine serum albumin, BSA) to monitor antibody responses
by ELISA. Mice immunization with glycoconjugate 69b showed that antibodies to the Brucella A
antigen could be produced and that these antibodies didn’t react in diagnostic tests based on the
M antigen. These findings were confirmed by the results of immunization studies with the OPS of
B. abortus strain S99, which contains 98% α-(1,2) and only 2% α(1,3) linkages conjugated to tetanus
toxoid. The OPS was subjected to an oxidation reaction using a procedure that concomitantly oxidized
all terminal D-Rhap4NFo residue, essentially destroying the M epitope [58]. Immunization studies
in mice showed that antibodies against the A epitope dominated. Taken together, all these studies
contributed to identify the main elements for a glycoconjugate vaccine candidate for brucellosis and
demonstrated that diagnostics based upon the M or A (terminal) epitopes can discriminate infected
from vaccinated animals.
6. Haemophilus influenzae Type b (Hib)
Haemophilus influenzae is a Gram-negative bacterium predominantly colonizing the human
respiratory tract. H. influenzae strains are divided into two subgroups: unencapsulated strains, also
named non-typeable (non-reactive with typing antisera) and encapsulated strains (reactive with typing
antisera) comprising six serotypes: a, b, c, d, e and f. In particular, serotype b strains (H. influenzae b,
Hib) cause severe diseases including meningitis, pneumonia and septicemia, especially in infants and
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children [59]. Hib CPS consists of a polymer of β-D-ribose-D-ribitol-5-phosphate (PRP) disaccharide,
characterized by the presence of a phosphodiester linkage between repeating units (Figure 8).
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The first generation of Hib vaccines, made with purified polyribosyl-ribitol phosph t , induced
relatively low titers of serum antibodies, insufficient to protect children from invasive disease [60],
and were replaced by Hib PS-conjugate vaccines (PedVaxHIB®, ActHib®, HibTiter®) [61]. Vérez
Bencomo et al. developed the first synthetic glycoconjugate vaccine in 2004 [9], QuimiHib®
(compound 70, Figure 8) using a one-pot polycondensation strategy starting from synthetic
β-D-ribose-(1,1)-D-ribitol-5-H-phosphonate derivative 71 and the phosphodiester-linked compound
72 [9]. Final conjugation to TT gave the fully synthetic glycoconjugate vaccine QuimiHib® [62],
which contains a mixture of oligosaccharides with six to eight repeating units on average. Recently,
Baek et al. [62] have reported the synthesis of CRM197 glycoconjugates of PRP oligosaccharides up to
decamers (compounds 73–76, Figure 9).
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Oligosaccharide synthesis was performed via H-phosphonate chemistry starting from
tetrasaccharide building block 77 and using a [4+4] iterative elongation strategy. Tetrameric, hexameric,
octam ic and decamer c PRP fragments were obtained using this iterative approach, followe by the
introduction of phosphodiester-linked spacer. Tetrasaccharide 77 was synthesized from disaccharide
78 (Figure 9), in turn obtai ed fro the dithioacetal building block 79. After conjugation to CRM197,
immunogenicity studies with the synthetic glycoconjugates 73–76 were performed in a rabbit model.
After immunization, sera IgG levels towards the PRP oligosaccharides were determined by glycan
array analysis. Tetramer conjugate 73 and oct mer conjugate 75 xhibited th highest mm nogenicity,
most likely indicating that four repeating u its are suffici nt for immu ogenicity, while the hexamer
conjugate 74 exhibited lower immunogenicity. This result was ascribed to the folding of the structures
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and to their different interaction with the immune system receptors. The authors concluded that
glycoconjugates of synthetic Hib PRP are immunogenic in a rabbit model and, in particular, tetrameric
conjugate 73 is a promising candidate for the design of a new glycoconjugate Hib vaccine.
7. Streptococcus pneumoniae
S. pneumoniae, a Gram-positive organism, is a major cause of pneumonia, otitis media, meningitis
and septicemia. Various virulence determinants of pneumococci have been identified including the
highly variable capsular polysaccharide (CPS), pneumolysin toxin and surface lectins. Bentley and
colleagues have determined the DNA sequence of the capsular biosynthesis genes for all 90 serotypes
(ST) of S. pneumoniae and found that each serotype has a different CPS composition [2,64]. The first
generation carbohydrate-based vaccine PPV23 (Pneumovax®, Merck) containing the 23 most prevalent
serotypes is available in the United States and in Europe, although conflicting data about its efficacy
have been reported [65]. To improve the immunogenicity, glycoconjugate vaccines like PCV7 (Prevnar®,
containing PS from serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F), PCV13 (Prevnar 13™, containing PS
from serotypes 4, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 1, 3 and 5) and PCV10 (GlaxoSmithKline’s
Synflorix™, containing PS from serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F) have been
licensed and commercialized. Although S. pneumoniae CPS-based glycoconjugate vaccines are in
current routine immunization programs and notwithstanding the increased coverage of strains,
diseases caused by serotypes not included in the above vaccines can increase in the long run [64,66].
Recent efforts have been dedicated to the synthesis of antigens from S. pneumoniae serotypes not
included in licensed formulations. Of note, glycoconjugates from synthetic fragments of S. pneumoniae
serotype 8 have been tested in coformulation with PCV13, as reported in Section 7.6. Recently,
the synthesis of the hexasaccharide repeating unit of S. pneumoniae serotype 12F, also not included
in marketed formulations, has been reported by Seeberger et al. [67]. Meanwhile, alternative and
combined approaches are emerging for vaccine development, based, for instance, on immunization
with a combination of bacterial lectins and surface polysaccharides. In a recent study, the surface
polysaccharide serotype 6B (PS6B) of S. pneumoniae was conjugated to a recombinant pneumococcal
surface protein A (lectin rPspA), a highly immunogenic surface protein produced by all strains of
S. pneumoniae, showing the ability of the novel conjugate to induce production of functional anti-rPspA1
and anti-PS6B antibodies [68].
7.1. S. pneumoniae Serotype 1
S. pneumoniae serotype 1 (ST1) CPS (Figure 10) contains the rare monosaccharide
2-acetamido-4-amino-2,4,6-trideoxy-D-galactose (D-AAT) bearing a free amine at C-4. Synthetic
fragments of ST1 CPS have been reported by Wu et al. [69], Christina et al. [70] and Schumann et al. [71].
In particular, Schumann et al. also contributed to the identification of the protective epitope of ST1 CPS.
ST1 is one of the serotypes difficult to target by vaccination due to the low levels of functional antibodies
induced by licensed glycoconjugate vaccines. This was recently [72] ascribed to the concealment
of the protective epitope during chemical activation and conjugation to carrier protein. Indeed,
conjugation strategies by means of reductive amination (PCV13) or 1-cyano-4-dimethylaminopyridine
activation chemistry (PCV10) could lead to partial destruction of the D-AAT moieties by reaction
with the free amines on this rare monosaccharide. To confirm this assumption Schumann et al. [72]
synthesized and tested fragments of ST1 CPS and of the closely related Bacteroides fragilils PS A1
CPS (Figure 10). Synthetic oligosaccharides 80–85 were then subjected to glycan microarray analysis
of ST1- and PS A1-directed antisera. Trisaccharide 80 bound to antibodies contained in ST1 typing
serum, while disaccharide 82, missing the D-AAT moiety, was bound in a much lower extent, revealing
the importance of D-AAT for immune recognition. Neither the PS A1 repeating unit 81 nor D-AAT
alone 83 or galacturonic acid alone 84 were bound. Trisaccharide 80 was then conjugated to CRM197
(glycoconjugate 86) by reaction with the thiol group, thus preserving the amino group of D-AAT.
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Immunization studies in rabbit models showed that glycoconjugate 86 elicited a higher immune
response against trisaccharid 80, D-AAT 83 as well a ST1 CPS compared to PCV13 or CRM197 alone.
The antibacterial properties of ser ag inst glycoconjugate 86 were evaluated in vitro and in vivo.
In particular, flow cytometry revealed that antibodies in sera from glycoconjugate 86-immunized
rabbits bound better to ST1 bacteria than sera from PCV13-immunized rabbits. Bacterial binding
correlated with serum opsonophagocytic killing capacities. Mice were passiv ly immunized with
serum of rabbits immunized with glycoconjugate 86 and t n transnasally infected with ST1
pneumococci, showing fewer bacterial colonies than mice pretreated with sera from PCV13 or
CRM197 alone-immunized rabbits. Given the importance of these findings, glycoconjugate 86 is
now advancing in preclinical development for inclusion in semisynthetic vaccines covering multiple
pneumococcal serotypes [72]. Interestingly, this work further demonstrates that the use of synthetic
oligosaccharide antigens may be rucial to unveil hidden protect ve epitope y means of site-selective
protein conjugation.
7.2. S. pneumoniae Serotype 2
ST2 is one of “nonvaccine serotype”, i.e., not covered by licensed PCVs based on capsular
polysaccharides. It is one of the main cause of invasive pneumococcal diseases (IPD) responsible
for pneumonia, septicemia, meningitis, and otitis media in many countries in Asia [73] and Central
America [74]. The structure of ST2 CPS is composed of a hexasac haride repeating unit illustrated in
Figure 11 [75].
Emmadi et al. [76] reported the synthesis of the repeating unit of ST2 CPS and of series of synthetic
glycans containing portions of the ST2 CPS (compounds 87a–93a), in order to identify the protective
oligosaccharide epitope. Hexasaccharide 89a (one repeating unit) was synthesized from disaccharides
94, 95, 96 via a [2+2+2] glycosylation strategy (Figure 11). These disaccharide units were in turn
synthesized from L-rhamnose and D-glucose building blocks 97–102 (Figure 11). The β-rhamnosidic
linkage in 94 was incorporated by installing a remote C3 picoloyl group on rhamnosyl thioglycoside 97
for hydrogen-bond-mediated aglycon delivery. The 1,2-cis linkage between glucose building blocks 101
and 102 was formed by in situ anomerization, by converting 102 to the corresponding glycosyl bromide
and then by reatcion with 101 in the presence of TBAI. Glycan microarrays containing oligosaccharide
fragments 87a–93a were used to screen human and rabbit sera specific to serotype 2 CPS and to identify
epitope hits. These experiments demonstrated that the α-D-GlcA-(1→6)-α-D-Glc-(1→2) branch is
important to have strong specific antibody binding. Hexasaccharide 89a was conjugated to CRM197
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and used for mice immunization producing very high titers of CPS-specific opsonizing antibodies
that efficiently fix complement and promote killing of pneumococci by phagocytic activity. An in vivo
experiment to evaluate the vaccine involved subcutaneous immunization of mice that were infected
with highly virulent ST2 strain NCTC7466. Neoglycoconjugate hexasaccharide-CRM197 89b stimulated
a T cell-dependent B cell response that induced CPS-specific antibodies resulting in the reduction of
the bacterial infection in lung tissues and blood.
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7.3. S. pneumoniae Serotype 3
The commercial anti-pneumococcal glycoconjugate vaccine PCV13 includes S. pneumoniae
serotype 3 (ST3). However, ST3 glycoconjugate contained in PCV13 has shown an atypical
immunogenicity, ascribed to the abundant CPS expression on the capsule and to a weakened booster
response leading to hyporesponsiveness (inability of the individual to mount an immune response
after booster vaccination) [77,78]. Indeed, the levels of pre-existing ST3-specific antibody were found
to be negatively correlated with the B cell memory response to a booster dose of PCV13 containing
ST3 glycoconjugate [79]. This behavior has been associated with a lack of protection against acute
otitis media [80]. As a consequence, one can assume that pure synthetic antigenic structures, designed
on the basis of antibody binding specificities, could improve immunogenic properties of ST3 CPS
conjugates. Synthetic oligosaccharides based on ST3 CPS repeating units have been already reported
by Benaissa-Trouw et al. in 2001 [80] and they have been proven to protect mice against lethal
intraperitoneal challenge with ST3 pneumococci. Recently, Parameswarappa et al. [81] reported the
synthesis of a library of oligosaccharides, compounds 103a–110a and their corresponding CRM197
conjugates 103b–110b (Figure 12).
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Figure 12. Repeating unit of Streptococcus pneumoniae 3 CPS and synthetic ST3 glycan fragments
reported in [81].
The synthesis of the fragments was achieved from disaccharide 111, in turn obtained from two
differentially protected glucose building blocks 112 and 113. Tetrasaccharide 110a was synthesized
with a [2+2] strategy in 13% overall yield from 112 and 113. The synthetic ST3 oligosaccharides
potentially contained the minimal protective glycan epitope (Figure 12). Glycan arrays containing
the different fragments were used to screen human sera for antibodies and to define the recognition
site of two protective ST3-specific monoclonal antibodies (mAbs). Tetrasaccharide 110a contains the
protective epitope of both mAbs and was selected for further immunogenicity studies. The CRM197
conjugate 110b elicited protective immunity as evidenced by opsonophagocytosis assays and mice
immunization experiments against experimental pneumonia caused by transnasal infection with
ST3 strain PN36. Formulation of the protective epitope has to be further evaluated to elicit optimal
long-term immunity.
The synthesis of ST3 CPS oligosaccharides 114–117 (Figure 13) has been recently reported by
Xiong et al. [82] These oligosaccharides were also designed to have different sugar residues, Glc
(114 and 116) or GlcA (115 and 117) at the upstream end. As an example, heptasaccharide 116 was
synthesized by a 3+[2+2] glycosylation strategy from trisaccharide 118 and disaccharides 119 and 120,
all achieved from common precursor 121. Hexasaccharide 115 was synthesized by a [2+2]+2 strategy
from disaccharides 122, 123 and 120. The oligosaccharides were designed to expose a free amino group
at their downstream ends (114a–117a) to allow conjugation with tetanus toxoid (TT) (114b–117b) and
BSA (114c–117c) carrier proteins. [83]. TT conjugates 114b–117b and free oligosaccharides 114a–117a
were injected in mice and the obtained antisera were analyzed by ELISA using BSA conjugates
114c–117c as capture antigens. Antisera derived from mice immunized with TT conjugates 114b–117b
contained significantly higher specific antibodies compared to 114a–117a. In particular, antibody titers
induced by 114b and 115b were significantly higher than those induced by 116b and 117b, showing
that the chain length of ST3 CPS oligosaccharides influences the immunological properties and that
longer oligosaccharides are not necessarily better haptens.
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Figure 13. Synthesis of ST3 oligosaccharides and glycoconjugates from [82].
7.4. S. pneumoniae Serotype 4
The CPS of S. pneumoniae serotype 4 (ST4) contains a rare and labile substituent, the trans-2,3-(S)
cyclic pyruvate ketal modified galactose (residue A, Figure 12). The ST4 repeating unit is a tetrasaccharide
made of [3)-β-D-ManpNAc-(1→3)-α-L-FucpNAc-(1→3)-α-D-GalpNAc-(1→4)-α-D-Galp-2, 3-(S)-Pyr-(1→]
(Figure 14).
Recently, the Seeberger group [84,85] reported the synthesis and immunological evaluation of
fragment 124a, corresponding to the repeating unit, and shorter oligomers 125a–131a with and without
the pyruvate ketal, demo strating the importance of the trans-2,3(S)-pyruvate ketal in the ST4 epitope.
In particular, the syntheti fragments were obtained with a linear glycosylation approach from building
blocks 132–135 (Figure 13). Of note, for the installatio of 1,2-cis li kages, glycosylati n of alactose
135 with donor 134 occurred with good stereoselectivity of the newly formed glycosidic linkage
(α:β = 7:1). On the other hand, installation of the final β-manno linkage in unit D was accomplished
using an indirect two-steps method. Indeed, exclusive β-glucosylation was achieved with donor 132
using NIS and TfOH as promoters. The following 2-OH activation and amination established the
desired manno configuration at C-2. Glycan arrays showed that ST4-directed antibodies in the human
reference serum (serum 007sp) [85] recognized both pyruvate-dependent and pyruvate-independent
epitopes. Oligosaccharide 124a showed the highest antibody affinity an cross-reactivity to ST4 CPS
in mice and h ma s immunize with the natural CPS. H man serum 007sp contains antibodies
recog izing also n n-pyruvalated oligosaccharides 129a and 131a. Thus, it was hypothesized that
non-pyruvalated epitopes could be present in the natural CPS, although non-pyruvalated epitopes
could be less immunogenic than pyruvalated epitopes, as indicated by lower antibody binding signals
to 129a and 131a compared to 124a. To verify this behavior, two selected CRM197 conjugates of
non-pyruvalated ST4 oligosaccharides, 129b and 131b, were used for mice immunization. The raised
antibodies did not recognize the natural polysaccharide on the surface of ST4 bacteria. This result
confirmed that the pyruvate motif on the oligosaccharide is needed for cross-reactivity with the
native CPS.
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7.5. S. pneumoniae Serotype 5
Serotype 5 (ST5) is the fifth most prevale t serotype of S. pneumoni e and is included in the
PCV10 and PCV13 [86]. ST5 CPS repeating unit (Figure 15) [87] contains a branched N-acetyl-
L-fucosamine (L-FucpNAc) linked to D-glucose (D-Glc) and D-glucuronic acid (D-GlcA) and two
rare deoxyamino sugars: the ketoamino sugar 2-acetamido-2,6-dideoxy-D-xylose-hexos-4-ulose (Sugp)
and the N-acetyl-L-pneumosamine (L-PneupNAc), which is α(1→2) linked to D-GlcpA. During CPS
isolation and purification for the production of the glycoconjugate vaccine, the keto group of Sugp can
be partially or fully reduced to form a mixture of ST5 CPS components with decreased immunogenicity
compared with the native ST5 CPS [88].
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Recently, Lisboa et al. [89] reported the synthesis of ST5 CPS fragments 136a–138a starting
from six differentially protected monosaccharide building blocks 139–144 (Figure 15). In particular,
L-fucosamine acceptor 143 and L-pneumosamine donor 144 were both synthesized from L-fucal 145 via
an azido-phenylsel ation re ction on the double bond. Among the oligomers synthesized, oligomer
136a contains N-acetyl-D-quinovosamine (A’, D-QuiNAc) in place of of Sugp (A), displaying a hydroxyl
group at C-4 in place of the labile carbonyl occurring in the native ST5 CPS. Seeberger group [89]
uncovered the protective ST5 CPS epitope using a combination of glycan microarray-based mAb
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generation and immunological evaluation performed in rabbit models. These experiments showed
that the rare aminosugar L-PneuNAc, as well as the branching, are essential for antibody recognition
and avidity. Interestingly, it was also demonstrated that CRM197 glycoconjugate 136b, containing
D-QuiNAc, induced higher antibody titers and opsonic activity compared to native ST5-CRM197
conjugate contained in PCV13 vaccine. Special care should be taken, however, in the interpretation
of the results obtained with such different vaccination modalities, i.e., a 13-valent vaccine vs. a
monovalent synthetic vaccine. The latter indeed contains only one type of carbohydrate which is
administered in much higher amount in comparison to the same carbohydrate contained in PCV13.
Nevertheless, this result suggests the possibility for the replacement of labile functional groups,
generating manufacture issues, with stable functional groups that do not affect the immunogenic
properties of glycoconjugates.
7.6. S. pneumoniae Serotype 8
ST8 is part of the first-generation polysaccharide vaccine PPV23, but it is not included in
glycoconjugate vaccines PCV7, PCV13 and PCV10. Many clinical ST8 isolates were found resistant
to antibiotics like erythromycin, clindamycin, tetracycline and ciprofloxacin [90]. Furthermore, this
multiresistant serotype is a major cause for concern in HIV-infected patients, where its occurrence
is significantly more frequent [91]. ST8 CPS consists of a linear tetrasaccharide repeating unit
(Figure 16) sharing a common cellobiuronic acid disaccharide [β-D-GlcA-(1→4)-β-D-Glc] with ST3
CPS (BA sequence, Figure 12).
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Schumann et al. [92] reported the pr paration of tetrasaccharide fr gments of ST8 CPS 146a–150a,
to identify the minimal protective glycan epitope. The four tetrasaccharides were synthesized by
automated glycan assembly, using solid-phase oligosaccharide synthesis, starting from building
blocks 151–156. Glycan microarray containing all ST8 CPS frameshifts led to the identification of
one tetrasaccharide frameshift (BAEC, 148a) that was preferentially recognized by a protective mAb,
a murine immunoglobulin M (IgM) against native ST8 CPS [93]. Conjugation with CRM197 of the
tetrasaccharide 148a gave the ST8 glycoconjugate 148b, which was used for immunization of mice and
rabbit models. Interestingly, although cellobiuronic acid disaccharide conjugate 103b (BA, Figure 12)
conferred protective immunity against ST3 [81], no ST3-directed immune esponse as found after
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mice immunization with conjugate 148b (BAEC), probably because of the different presentation of
cellobiuronic acid in the ST8 sequence. Conjugation with CRM197 and coformulation with PCV13 of
either tetrasaccharide 148a or its congener tetrasaccharide 150a (AAEC), containing a D-Glc residue in
place of the naturally occurring D-GlcA, led to a new vaccine which conferred protective immunity in
rabbits against all the 14 S. pneumoniae serotypes. This achievement confirms the possibility of adding
synthetic oligosaccharide antigens to existing vaccines with the aim of expanding current formulations
and replacing serotypes that are not efficiently targeted.
7.7. S. pneumoniae Serotypes 14 and 19F
Among the synthetic glycoconjugate vaccines for S. pneumoniae, gold nanoclusters have been
recently explored, highlighting the potential of these carriers for the development of synthetic
vaccines [94,95]. In particular, glyconanoparticles bearing the synthetic tetrasaccharide epitope of
S. pneumoniae type 14 (ST14) PS have been recently reported [96]. ST14 PS consists of repeating
units of the tetrasaccharide (6)-[β-D-Galp-(1→4)-]β-D-GlcpNAc-(1→3)β-D-Galp-(1→4)β-D-Glcp-(1→)n
(Figure 17) [97].
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The synthetic branched tetrasaccharide Gal-Glc-(Gal-)GlcNAc (157a), synthesized and studied
by Mawas et al. [99] was identified as the smallest structure producing protective antibodies
against ST14 when conjugated to CRM197 protein (glycoconjugate 157b) [100]. Tetrasaccharide 157c,
derivatized with a terminal thiol for nanoparticle functionalization, was conjugated together with the
T cell-stimulating ovalbumin peptide (OVA 323–329) and D-glucose fragment 158 to produce small
(2 nm) hybrid gold glyconanoparticles 159 (GNPs, Figure 17). Immunogenicity studies in mice showed
that 159 induced the production of specific IgG antibod es gainst ST14 PS. The presence of OVA
323–339 pepti e was necessary for the induction of high affin ty IgG antibo ies, while the T cell epitope
did not raise anti-OVA 323–339 peptide antibodies, thus avoiding the risk of epitope suppression. Sera
obtained from mice immunized with 159 with a ratio of tetrasaccharide:Glc:OVA 323–339 = 45:50:5
were able to opsonize ST14 bacteria, although less efficiently than sera from mice immunized with
native ST14 PS conjugated to CRM197. These results make 159 a promising S. pneumoniae type 14
vaccine candidate.
In another recent study [98], gold glyco-nanoparticles (GNP) were prepared with synthetic
oligosaccharide fragments corresponding to the re eating units of S. pneumoniae CPS type 19F and
14. In particular trisacchari 140a, corresp nding to ST19F repeating unit [β-D-ManpNAc-(1→4)-α-
D-Glcp-(1→2)-α-L-Rhap-(1→] (Figure 17), was prepared according to procedures described in the
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literature [101,102] and derivatized as thiol-ending ligand 160b. Tetrasaccharide 157c (fragment of
ST14), trisaccharide 160b (fragment of Pn19F), D-glucose fragment 158 and OVA 323–339 peptide were
loaded onto GNPs (161, Figure 17) in different ratios. After mice immunization, GNPs 161 enhanced the
production of specific IgG antibodies toward ST14 PS, while no IgG antibodies against ST19F PS were
elicited. In particular, the titers of specific IgG antibodies towards ST14 polysaccharide raised by 161
were higher than the titers elicited by GNPs exclusively displaying ST14 (159), and comparable with
commercially available PCV13. Of note, this work explored the effect on the immunological response
of glyconanoparticles displaying two carbohydrate epitopes from different bacterial serotypes.
8. Group A Streptococcus
Group A Streptococcus (GAS) is a Gram-positive microorganism causing post-sequelae autoimmune
infections including rheumatic heart disease. The main driver of autoimmunity is the surface-anchored
GAS M polymorphic proteins [103]. Indeed, formulated multivalent M protein-based vaccines were
tested in animal and human models but they are protective only for the serotypes included in
formulation. For this reason, the identification of a common protective antigen is highly desirable.
Due to its prominence in the GAS cell wall and its conservation across all GAS strains, the
Lancefield group A carbohydrate (GAC) has been considered as a potential antigen for a universal
GAS vaccine [103]. The Lancefield group A carbohydrate (GAC) consists of a α-L-Rhap(1→3)-α-
L-Rhap(1→2)-[β-D-GlcpNAc]-(1→3) repeating unit (Figure 18).
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Increasing concerns regarding autoreactivity of antibodies that recognize the native GAC GlcNAc
side chain (anti-GlcNAc onoclonal antibodies) [105], however, have been supported by recent
studies [106,107]. Cross-reactivity (especially in hea t or brain tissues) of nti-GlcNAc mAb was
hypothesized almost twenty years ago [108] and it is still a crucial point of discussion, as well
as the role of polyrhamnose on the immunogenicity. More recently, Henningham et al. [109]
reported that the relative contribution of GlcNAc side chains to the innate i mune resistance of
GAS varies among strains and that GlcNAc side chain is not a universal GAS virulence factor in
animal models. In 2010, Kabanova et al. [104] reported the synthesis of two sets of hexasaccharide-
and dodecasaccharide-CRM197 conjugates 162b–165b (Figure 18) and compared their immunogenicity
with the native GAC-CRM197 conjugate. All oligomers 162a–165a were synthesized starting from
building block 166 and 167. Of not , the GAC isolated from bacterial fermentation was found to be
contaminated with polyrhamnose variant species. The synthetic oligosaccharide conjugates 162b–165b
showed similar immune response in mice compared to GAC conjugate against two GAS isolates of M1
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and M23 serotypes. A saccharide chain length of six (the minimal size of the antigen) was found to be
sufficient to elicit protective antibodies.
More recently, Auzanneau et al. [110] reported the synthesis of hexasaccharide 164a and its
conjugation to TT carrier protein to give 164c. Previously reported conformational analysis had shown
that the branch-point in the trisaccharide repeating motif was important for antibody recognition in the
antibody-ligand complex [111]. Epitope mapping of a branched trisaccharide and a doubly-branched
hexasaccharide by saturation transfer difference NMR methods [112] confirmed the importance of the
branched trisaccharide epitope that was studied in binding experiments with a mouse monoclonal
antibody. The immunogenicity of the synthetic hexasaccharide–TT conjugate 164c was confirmed by
primary (IgM) and secondary antibody (IgG) responses, with anti-hexasaccharide titers that increased
after booster immunizations to mice. These titers were similar to those obtained with the native
GAC–TT conjugate.
9. Group B Streptococcus
Streptococcus agalactiae or Group B Streptococcus (GBS) is the leading cause of invasive infections
in pregnant women [113], newborns, and elderly people, resulting in pneumonia, sepsis and
meningitis [114,115]. GBS is a multiserotype Gram-positive bacterium that expresses Lancefield
group B polysaccharide as a major virulence factor. Ten different serotypes of GBS PS have been
characterized (Ia, Ib, II, III, IV, V, VI, VII, VIII, IX), but five of them (Ia, Ib, II, III and V) account
for the vast majority of the disease [116]. Chemical synthesis of the repeating unit of some of these
serotypes (types Ia, II, V) have been reported in recent years by Guo and Gao groups [117–119].
These works may be useful for the synthesis of other fragments of GBS PS and for further
investigations, like antigenicity and immunological studies. GBS type III repeating unit is composed
of →4-β-D-Glcp-(1→6)-β-D-GlcpNAc-[α-NeuNAc-(2→3)-β-D-Galp-β-(1→4)]-(1→3)-β-D-Galp-(1→
(Figure 19).
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Baker et al. [113,120] reported that GBS PSIII conjugated to TT carrier protein resulted in high
tolerance when administered to pregnant women, raising highly specific IgG Abs titers which were
transferred through the placenta to infants. Chemical synthesis of fragments of PSIII and of related
desialylated fragments have been reported [121–124]. Conformational studies and molecular dynamics
simulation [125,126] showed high flexibility of GBS PSIII, as it adopts partial h lical conformation
thanks to the presence of α-NeuNAc-(2→3)-β-D-Galp-β-(1→4) branch, while without the sialic acid
residues a random coil conformation is preferred. In particular, it has been shown that there is a
specific interaction between the sialic acid residues and the glucosyl and galactosyl backbone which
influences the orientation of the side chain and the backbone conformation [125,126]. These behaviors
have been ratio alized hypothesizing the existence of a extended conformational epitope. A recent
study carried ut by Adamo e al. [127] showed that synthetic fragments of GBS PSIII conjugated to
CRM197 are recognized by polyclonal PSIII specific serum and that the presence of the branch is a
structural relevant motif for the recognition of anti-PSIII antibodies. Even if these neo-glycoconjugates
can’t still be considered vaccine candidates, this promising result paves the way to the use of synthetic
GBS PSIII oligosaccharide as tools to study their detailed molecular interactions with anti-PSIII mAbs.
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10. Salmonella Typhi
Salmonella enterica serovar Typhi, generally termed Salmonella Typhi (S. Typhi) is a highly invasive
encapsulated Gram-negative bacterium, responsible for typhoid fever, a systemic infection mostly
diffused in less-developed geographic areas, lacking proper sanitary conditions. Infections occur
generally via consumption of contaminated food and water. Global estimates of typhoid fever burden
range between 11 and 21 million cases and approximately 128,000 to 161,000 deaths annually [128],
with a peak incidence in individuals from early childhood to 15 years old [129]. Clinical diagnosis of
the infection is difficult due to the often non-specific symptoms of typhoid fever that can be confused
with other common febrile illnesses [130] and due to serological tests that often give false-negative and
false-positive results [131,132]. S. typhi capsule contains three antigens: the H antigen is a heat sensitive
protein of the peritrichous flagellae, while the O or somatic antigen is a cell-wall lipopolysaccharide.
The Vi antigen is the capsular polysaccharide which overlies the O antigen. The Vi antigen plays a
crucial role in the modulation of early inflammatory responses during S. Typhi infections [133,134]
and represents the basis for the formulation of vaccines against this bacterium [134–136]. It is called
Vi (“Virulence”) antigen due to its ability to enhance S. Typhi virulence [137,138]. It is an anionic
polymer composed byα-(1→4)-linked N-acetyl galactosaminuronic acid repeating units predominantly
O-acetylated at position 3 (Figure 20). The degree of 3-O-acetylation ranges from 60% to more
than 90% in some strains and the immunogenicity of Vi antigen is closely related to its degree of
O-acetylation [139]. The carboxylic acids are less exposed and partially shielded by the O-acetyls and
this can explain the minor effect upon the immunological properties observed after reduction of the
carboxylic acids [139].
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Although pure polysaccharide vaccines based on the purifi d Vi antig have been proven
effective in adults, they have bee so far ineffective in infa ts (especially children younger than 5 years
of age), in the elderly and immunocompromised individuals [143]. The coupling of S. Typhi CPS
fragments to carrier proteins (rEPA, TT, CRM197) produced glycoconjugate vaccines able to elicit a T
cell dependent immune response [144,145]. In particular, the conjugate vaccine Vi-TT was recently
found effective in the prevention of typhoid fever in a phase 2b trial and proven to be safe and
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highly immunogenic [146]. The injectable Vi-TT conjugate vaccine (TCV) is currently licensed and
recommended by WHO for children from 6 months of age and adults up to 45 years of age. Synthetic
oligomers of Vi antigen were first reported in the literature by Sinaÿ and coworkers [140]. In particular,
Vi oligosaccharides up to hexasaccharide 168–172 (Figure 20) bearing an unnatural O-methyl group
both at the C4 position of the upstream residue and at C-1 position of the downstream residue have been
synthesized, thus precluding protein conjugation [140]. Recently, Ye and co-workers [141] reported
the synthesis of Vi oligomers 173–176 as methyl glycosides containing an unnatural acetyl group at
C-4 of the upstream residue (Figure 20). In particular, N-acetyloxazolidinone-containing glycosyl
donor 177 and acceptor 178 were used to direct alpha stereoselectivity during glycosylation reactions.
ELISA competitive assays showed that synthetic tri- and tetra-saccharides 174 and 175 had improved
antigenic activities in comparison to Sinaÿ fragments [140]. The authors speculated that improved
affinities could be ascribed to the presence of an acetyl group at C-4 of the upstream residue in place
of the methyl ether present in Sinaÿ’s structures. More recently, Ye et al. [142] synthesized a series of
Vi pseudo-oligosaccharides 179–183 (Figure 20) conjugated by carbon chain spacers through olefin
cross metathesis or by the 1,2,3-triazole moiety through Huisgen cycloaddition reaction. The binding
affinities to anti-Vi antibodies of proposed mimics 179–183 were investigated, showing that the affinity
of divalent compounds was generally comparable to the monovalents of the same length. For example,
the affinity of 181, containing the butylene linker did not increase significantly when compared with
that of monovalent tetrasaccharide. Heterodimer 182, which mimics the native Vi antigen with the
similar chain-elongation direction did not result in improved antigenicity, perhaps suggesting that
longer Vi oligomers are needed for higher affinity.
Recently, the synthesis of di- and trisaccharide fragments of S. Typhi Vi capsular polysaccharide
analogues and their zwitterionic counterparts has been accomplished by the Lay group (Figure 21) [147].
These fragments were composed of N-acetylgalactosaminuronic acid repeating units non-acetylated
at position 3 (Figure 21). The synthetic strategy was designed in order to obtain the two distinct
series of oligomers 184–187 (2-acetamido derivatives and their zwitterionic analogues) from common
building blocks, donor 188 and glycosyl acceptor 189, in turn synthesized from commercially available
D-galactosamine hydrochloride. Glycosylation reaction of acceptor 189 with donor 188 gave exclusively
the desired α (1,4) disaccharide and the same 1,2-cis stereoselective outcome was observed for
the trisaccharides.
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ELISA tests showed that oligosaccharides 184–187 were recognized by specific anti-Vi polyclonal
antibodies in a concentration-dependent manner with similar efficacies, lower than the natural Vi
polysaccharide. This might be related to the short chain length of the synthetic fragments and to the
lack of the 3-O-acetyl group, which has been reported as being important for the immunogenicity [139].
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11. Pseudomonas aeruginosa
Pseudomonas aeruginosa is an opportunistic Gram-negative bacterium that can cause
hospital-associated infections, often life-threatening in critically ill patients [148]. Cystic fibrosis
patients often become infected with P. aeruginosa in chronic lung infections [149]. P. aeruginosa encodes
several multidrug efflux pump genes [150] and has acquired multiple resistance mechanisms to most
antibiotic classes, selected by years of antibiotic treatments [151]. In the past few years, new approaches
such as the administration of anti-bacterial monoclonal antibodies are being investigated for the
prevention or treatment of P. aeruginosa infections [152]. In a recent study, P. aeruginosa bloodstream
infection isolates from patients with acute P. aeruginosa infections were analyzed for the ability to
express PcrV, a type 3 secretion protein, and Psl exopolysaccharide, an important component of the
microbial biofilm extracellular matrix [153]. The study showed that the majority of isolates expresses
PcrV and Psl. However, most of the patient’s sera lacked IgG and functionally active responses
to these targets. These findings suggest that Psl can shield the bacterium from the host immune
response, allowing the survival of the bacterium [153]. In particular, Psl is a serotype-independent
antigen anchored to the cell surface in a helical pattern, an organization that can be crucial for cell–cell
interactions and to engage in interaction with other biofilm-initiating components [154,155].
Di Giandomenico et al. [156] reported the identification of mAbs, classified in class I, II, and III
antibodies, binding three different epitopes of Psl, as suggested using competition antibody binding
assays. The mAbs possessed opsonophagocytic killing activity and anti–cell attachment activity.
In particular, class I mAb were shown to be the most functionally active and protective anti-Psl
antibodies against P. aeruginosa [156]. The repeating unit of PsI of P. aeruginosa is the pentasaccharide
shown in Figure 22, as determined by Kocharova et al. [157]. The chemical synthesis of different
fragments of PsI, tetra-, penta-, hexa- and decasaccharide 190a–193a was reported starting from
building blocks 194–199 (Figure 22) [158].
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The synthetic strategy dealt with the stereoselective glycosylation of mannosides and the
formation of two 1,2-cis mannosides, one of which is also extended at C-1, C-2, and C-3 in a
crowded 1,2,3-cis configuration. In particular, 4,6-O-benzylidene protected mannosyl donors [159]
194 and 195, modified by a C-3 Nap ether and a C-2 silyl ether, respectively, provided optimal ,2-cis
stereoselectivity in the glycosylatio reactions. On the other han , mannosyl donor 196, functi nalized
wi h a participating acetyl ester at C-2, resulted suitable for the preparation of 1,2-trans mannosides.
Co pounds 190a–193a were used to i entify the epitop r quirements of monoclonal antibodies
of class I, II, and III, showing some new insights about immune recognition of P. aeruginosa Psl
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exopolysaccharide [158]. Oligosaccharides 190a–193a were conjugated to BSA (190b–193b) to facilitate
coating of ELISA plates followed by testing reactivity with an antibody that bound each epitope class.
The class II mAb reacted potently with all oligosaccharides, suggesting that the epitope for this class
resides within tetrasaccharide 190b and does not require the 1,2-cis mannoside of compound 191b. The
class III antibody did not bind tetra- (190b) or pentasaccharide BSA-conjugate (191b). On the contrary,
it showed weak affinity to glycoconjugate 193b and strong affinity to glycoconjugate 192b, suggesting
that the terminal glucoside contained in glycoconjugate 192b is required for optimal binding. The class
I antibody did not bind any of the oligosaccharides, suggesting the possibility that the class I mAb
binds to a conformational epitope of PsI or to a substructure yet to be determined. The identification of
this epitope could provide an attractive lead compound for the development of a synthetic Psl-based
vaccine for P. aeruginosa.
12. Neisseria meningitidis
Neisseria meningitidis is a Gram-negative bacterium that colonizes the mucous membranes of
humans. Meningococcal meningitis and sepsis are severe diseases that kill children and young
adults within hours despite the availability of effective antibiotics. Mortality rates and permanent
disability, like amputation, hearing loss and neurologic deficiency associated with N. meningitidis
infections are high, even in countries where optimal health care practices are in place [160]. Among
the 12 serogroups of N. meningitidis [161], serogroups B, C, Y and W cause approximately 90%
of invasive meningococcal infections. Group A, however, is the only meningococcal serotype
capable of causing of meningitis epidemics. Serogroups B and C express α-(2,8)- and α-(2,9)-linked
polysialic acid, respectively. Alternating sequences of D-galactose or D-glucose and sialic acid are
expressed by serogroups W and Y [162,163]. The serogroup A capsule is composed of α-(1,6)-linked
N-acetyl-D-mannosamine-1-phosphate repeating units, partially acetylated at 3-OH (about 70%) and
4-OH (10–30%) [164]. First generation polysaccharide-based vaccines against N. meningitidis comprise
the bivalent (groups A and C), the trivalent (groups A, C and W), and the tetravalent (groups A, C, Y
and W) forms. Among second generation meningococcal glycoconjugate vaccines, three monovalent
group C conjugate vaccines and one tetravalent meningococcal conjugate vaccine against groups
A, C, Y and W are currently available. Of note, serogroup B (Men B) is not included in current
formulations and remains a major cause of endemic meningitis in both developed and developing
countries. The main obstacle for group B polysaccharides vaccine development is that the group
B polysaccharide, composed of α-(2,8)-sialic acid polymers, is expressed in a number of human
neurologic tissues since early fetal development. Men B CPS is therefore perceived as self-antigen
by the innate immune system and it induces immune tolerance. Structural modification of this “self”
antigen replacing the N-acetyl group of sialic acid units with an N-propanonyl group [165] induced
high levels of bactericidal IgG antibodies without detection of autoantibodies [166]. However, its
development has been suspended due to the poor performance of the vaccine in a limited human
trial and to the high perceived risk of autoimmunity [61]. A new type of group B vaccine, Bexsero®
(GlaxoSmithKline) developed by conjugation of three recombinant surface antigens (PorA, NadA
and fHbp) and outer membrane vesicles from group B strain NZ98/254, is now licensed in more
than 35 countries worldwide, including the EU, Australia, Brazil, Canada, Chile, Uruguay and the
USA [167–169]. More recently, a new anti-MenB vaccine based on two recombinant lipidated factor H
binding protein (Trumenba®, Pfizer) has been licensed by FDA and approved for use in EU countries
in 2017.
12.1. N. meningitidis Serogroup A (MenA)
N. meningitidis serogroup A is most often implicated in seasonal epidemic diseases, especially
in sub-Saharan Africa and asian developing countries [170,171]. The MenA CPS structure consists of
(1→6)-linked 2-acetamido-2-deoxy-α-D-mannopyranosyl phosphate repeating units, with about 70%
of O-acetylation at 3-OH (Figure 23).
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The synthesis of MenA CPS fragments wa reported in 2002 by Pozgay [173] and by Os arson
in 2005 [174], and upon conjugation to HSA the synthetic fragments were found to be immunogenic.
MenA CPS, however, suffers from poor stability in water, due to the chemical lability of the
phosphodiester linkages involving the anomeric position of each repeating unit. This issue stimulated
the design of novel and hydrolytically stable analogues of MenA CPS repeating unit, like carbocyclic
analogues (Figure 23) [172] and 1-C-phosphono analogues (Figure 24) [175,176], where a methylene
group replaces the pyranose oxygen atom or the anomeric oxygen, respectively. The conformational
behaviour of these analogues was investigated through DFT calculation and NMR spectroscopy [177],
with a particular focus on the orienta ion of the phosphate or ph sphonate aglycone and n the
possibility of pyr nos ring inversion [178]. The co parison b twe n mimics nd natural fragment
showed the preservation of the 4C1 geometry in both classes of analogues. The synthesis of carbocyclic
stabilized analogues of MenA CPS fragments was reported by the Lay group with the obtainment
of monomer 200a, dimer 201a and trimer 202a of carba-N-acetylmannosamine-1-O-phosphate.
The formation of the phosphodiester bridges was achieved through the use of the H-phosphonate
methodology [179], followed by functionalization with a phosphodiester-linked aminopropyl spacer
to allow protein conjugation. Oligomer synthesis was achieved starting from carbasugar 203, derived
from compound 204. Carbocycle formation was carried ut by Claisen rearrangement of glucal 205,
in turn obtained from commercially ava lable glucal 206 [172,177]. The inhibition abilities of the
synthetic molecules were investigated by a competitiv ELISA assay, showin that carba-disaccharide
201a is recognized by a polyclonal anti-MenA serum with an affinity similar to a native MenA
oligosaccharide with average polymerization degree of 3 [172]. The conjugation of carbocyclic
analogues 200a–202a to the protein carrier CRM197 gave glycoconjugates 200b–202b (Figure 23) that
were tested for immunogenicity [180]. MenA fragments, produced by mild acid hydrolysis of native
MenA polysaccharide (average degree of polymerization from 6 to 15) and conjugated to CRM197
were used to compare the activity of 200b–202b. Upon mice immunization, all glycoconjugates
elicited antibodies that reco nized the respective structures, although only co jugated trimer 202b
was able to induce specific anti-MenA IgG antibodies with detectable in vitro bactericidal activity.
Compound 202b, however, elicited antibodies to a lesser extent than hexamer and pentadecamer
conjugated oligomers 207 and 208 obtained from hydrolysis of the native polysaccharide, suggesting
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that hydrolytically stable analogues of MenA CPS can be used for the development of vaccine and that
conjugates with longer carbocyclic oligomers could further increase the induced immune response.
In addition, a strategy for the multivalent presentation of carba analogues was developed [181]
allowing conjugation of monomer 200a and dimer 201a to the metallic surface of superparamagnetic
iron oxide nanoparticles (SPION) to generate 200c and 201c (Figure 23). SPIONs can act as multivalent
carriers and as a contrast agent for magnetic resonance imaging (MRI) [182]. Functionalized SPIONs
dispersed in aqueous media can aggregate into clusters inducing a reduction of T2 [183] and this event
can be monitored as a decrease in brightness of a T2-weighted MR image [183,184]. This property
has been widely used for ligand detection in biological media [185]. SPIONs 200c and 201c were
produced as approximately spherical nanoparticles, with a size dispersion of 13± 3 nm and an average
particle coating of 320 unities per nanoparticle for 200c and of 160 ligands per nanoparticle for 201c,
as determined by transmission electron microscopy (TEM). Both 200c and 201c were able to bind the
polyclonal anti-MenA antibody, as evaluated by MRI analysis, exploiting the magnetic peculiarity
of SPIONs.
The synthesis of C-phosphono analogues of N. meningitidis group A CPS oligomers was reported
by the Oscarson [176] and Lay [186] groups. In particular, an improved strategy for the synthesis
of monosaccharides 209a–210a and phosphonoester-bridged fragments 211a–213a was recently
reported [175] starting from compound 214, 215 and 216. The introduction of the phosphonate
moiety was accomplished on alcohol 217, obtained from α-C-allenyl derivative 218 which, in turn, was
prepared in six steps from orthoester intermediate 219 (Figure 24).
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Figure 24. Retrosynthetic strategy for the synthesis of C-phosphono analogues of MenA CPS reported
in [174] and multivalent presentation of the fragments [181].
Competitive ELISA assay showed that monosaccharides 209a–210a and synthetic fragments
211a–213a containing the unnatural phosphonoester linkage were recognized by a human polyclonal
anti-MenA serum [175]. The comparison with the inhibition of either MenA (positive control) or
MenY (negative control) indicated that the chain lengths of the saccharide molecules is important
for the efficacy, while the presence of the phosphonate residue (comparison between compounds
211a–213a and glycosides 209a–210a) and the orientation of the anomeric linker (comparison between
compounds 211a and 212a) did not affect the affinity. Multivalent presentation on gold nanoparticles
of monomer 209a, dimer 211a and trimer 213a wer obtai ed (GNPs 220, 221 and 22 respectively,
Figure 24) [187]. Interestingly, nanoparticles 220, 221 and 222 showed a more tha three or er of
magnitude higher binding affinity than their counterparts not bound to the gold cluster 209a, 211a and
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213a, at the same nominal concentration of saccharides. Fallarini et al. [188] used functionalized gold
nanoparticles to test their ability to induce immune cell responses as a consequence of multivalency.
In particular, monodisperse gold nanoparticles (2 and 5 nm) coated with mono- and disaccharides
(220 and 221) were synthesized. Conjugation to gold nanoparticles conferred to the saccharides the
ability to activate macrophages and this property is dependent on the size of the nanoparticles, with
5 nm nanoparticles giving comparable results to those obtained with the polysaccharide bacterium
capsule (MenA) used as a natural antigen. Activation of macrophages occurred, independently of
the saccharide oligomerization (or charge) on the nanoparticle surface. However, only nanoparticles
220, exposing a phosphonodisaccharide-functionalized monolayer, induced T cells proliferation and
the increase of released interleukin-2 levels, the latter being a typical marker of T cell activation.
Recently, HSA conjugates 209b, 211b and 213b [189] were shown to induce both T cell proliferation
and interleukin-2 release in vitro, and to stimulate moderate specific IgG antibody production in vivo.
All HSA-conjugated compounds 209b, 211b and 213b induced T cell proliferation (40% of proliferation
at 102 µM), whereas only phosphonodisaccharide 211a was effective (28% of proliferation at 102 µM)
among the unconjugated forms, showing the unusual behavior of triggering T cell proliferation in vitro
and causing interleukin-2 release.
12.2. N. meningitidis Serogroup C (MenC)
N. meningitidis group C CSP is a α-(2,9)-polysialic acid with sporadic 7/8-O-acetylation
(Figure 25). Non-acetylated fragments have been shown to be immunogenic and to elicit an
immune response that is effective in recognizing and killing the bacterium [190]. A series of
non-acetylated α-2,9-oligosialic acids of different length 223a–233a were prepared by a convergent
synthetic route employing 5N,4O-oxazolidinone-protected phosphate-based building blocks 234 and
acceptor 235 [191]. The dodecamer was synthesized with a [4+8] strategy that allowed to retain the
α-selectivity even when the size of donor and acceptor increased.
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Figure 25. Repeating unit of MenC CPS and synthetic fragments reported in [191,192].
In a further study, di-, tri-, tetra-, and penta-sialic acids 223a–226a were coupled with KLH carrier
protein and studied for immunogen ity [192]. The glycoconjugat licited robust T cell-me iated
immunity in mice, in particular the immunogenicity of the tested oligo sialic acids increased in the
order tri(224b) > di(223b) > tetra(225b) > penta(226b). The antibodies elicited were tested for efficacy
and specificity, verifying if they could recognize and target group C N. meningitidis. All of the antisera
obtained with the oligosaccharide-conjugates 223b–226b had strong binding to the N. meningitidis cell
and no significant binding to cells not expressing α-2,9-poly and oligosialic acids (sialoglycans sTn,
GM3, GM2, α-2,8-linked polysialic). The α-2,9-trisialic acid was identified as a promising antigen for
developing glycoconjugate vaccines against group C Neisseria meningitidis. Recently, α-2,9-oligosialic
acid fragments (di-, tri-, te ra-, and p nta, 223a–2 6a) were conjugated with monophosphoryl lipid
A (MPLA), a known i mun tentiator (molecule with adjuva t activity) [193]. Immunological
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studies of the conjugates 223c–226c (Figure 25) in mice revealed that they elicited robust immune
responses, mainly IgG2b and IgG2c, consistent with T cell dependent immunities. In particular, the
immune response was comparable to the corresponding KLH-conjugates 223b–226b plus adjuvant.
The immunogenicity of oligosialic acids decreased with elongated sugar chain, although all tested
MPLA conjugates exhibited strong immune responses. The dimer 223c, actually, induced the highest
titers of antigen-specific total and IgG2b antibodies, but some of the produced antibodies did not
bind to oligosialic acids or bacterial CPS. In contrast, the tri- and tetra-sialic acid−MPLA conjugates
224c–225c, were fully effective showing the highest binding to bacterial cells and were identified as
promising vaccine candidates worthy of further investigation.
12.3. N. meningitidis Serogroup W (MenW)
N. meningitidis serogroup W CPS consists of a glycan repeating unit of [→6)-α-D-Galp-(1→4)-α-
D-Neup5Ac(7/9OAc)-(2→] (Figure 26). The synthesis of MenW CPS oligosaccharides of various
lengths was performed by Wu group in 2013 [194], with the aim of studying the relationship between
oligosaccharide length and immunogenicity.
Oligomers up to decasaccharides 236a–240a were obtained starting from protected disaccharides
241 and 242, bearing a N-acetyl-5-N,4-O-oxazolidinone (Figure 26), in turn synthesized from sialyl
phosphate donor 243, functionalized with an oxazolidinone and a phosphate leaving group to increase
the α-selectivity, and galactosides 244 and 245. Compound 243 was prepared from compound 246.
Oligosaccharide elongation was accomplished by iterative glycosylation and deprotections, using
disaccharide 241 for the [2+n] glycosylation reactions. After conjugation with CRM197, immunization
of mice and glycan array analysis of produced antisera showed that antibodies induced by conjugated
disaccharide 236b recognized only the disaccharide itself and did not cross react with longer oligomers.
In contrast, antibodies induced by glycoconjugates 237b, 238b, 239b and 240b all recognized tetra- to
decasaccharides, but not disaccharides. A serum bactericidal assay was used to study the bactericidal
activity of the antibodies and showed that 236b did not induce antibodies with bactericidal activity.
On the contrary, longer oligomers could and in particular, the tetramer 239b elicited antibodies with
the highest bactericidal effect. Taken together, these data suggested that the tetrasaccharide is the
minimum saccharide length required to induce bactericidal antibodies.
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12.4. N. meningitidis Serogroup X (MenX)
Serotype X of N. meningitidis (MenX) emerged as a substantial threat to public health, especially in
the “meningitis belt” area, after the introduction of MenA vaccine (MenAfriVac) and other conjugate
vaccines (consisting of MenA, C, Y and W serotypes) that do not provide coverage for MenX
serotype [195,196]. As a consequence, there is the need to extend the protection of current vaccines,
developing more comprehensive conjugate vaccines [197]. The MenX CPS is a homopolymer of
2-acetamido-2-deoxy-α-D-glucopyranosyl phosphate moiety (Figure 27) [198,199].
In 2013 Morelli et al. reported the synthesis of monomer 247a, dimer 248a and trimer 249a of
N. meningitidis X CPS [200], starting from intermediates 250–252, in turn derived from D-GlcNAc.
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Figure 27. Repeating unit of MenX CPS and synthetic fragments reported in [200–202].
In 2014 an improvement of the synthesis of MenX fragments, their conjugation to CRM197 and
the immunological evaluation of the resulting conjugates 247b–249b was reported [203]. Upon
mice immunization, the conjugated trimer (249b) was found as the minimal fragment possessing
immunogenic activity, although significantly lower than pentadecasaccharide-conjugate 253 obtained
from the native polymer and used in the same study. This finding suggests that oligomers longer
than three repeating units were possibly needed to mimic the activity of the native polysaccharide.
The following year, Harale et al. reported an alternative synthesis of the tetrameric fragment of MenX
CPS 254a, lacking the phosphate at the downstream end, starting from intermediates 251 and 225 in
turn synthesized from monosaccharide 256 (Figure 27) [201]. Competitive ELISA experiment, using
MenX bacterial CPS as a control, gave a concentration-dependent inhibition of anti-MenX antibodies
from both compound 254a (unconjugated synthetic MenX tetramer) and tetramer-TT conjugate 254b.
Lower inhibition for unconjugated frag ent 254a (up to 68% inhibition) was observed compared to
its conjugate form 254b (up to 89% inhibition) at all antigen concentrations tested. Also, bacterial
MenX CPS showed higher inhibition than synthetic compounds at all respective concentrations
used [201]. Very recently, an alternative strategy for MenX oligomer synthesis (Figure 27) was
developed [202], based on an enzyme-catalyzed one-pot elongation of synthetic trimer 257a. Oligomers
with predefined average length (compound 258a for general formula of avDP = 12) were synthesized
and conjugated to CRM197. Mice immunized with 258b elicited functional antibodies comparable to
controls immunized with the current MenX glycoconjugates prepared from the natural CPS or from its
fragments enzymatically produced.
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13. Mycobacterium tuberculosis
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains one of the leading causes
of death in the world. In 2016, some 1.7 million people died from the disease, with 64% cases of
the total occurring in India, Indonesia, China, Philippines, Pakistan, Nigeria, and South Africa [204].
Moreover, it is estimated that one-third of the human population is latently infected with M. tuberculosis
and is highly vulnerable if immunocompromised (in 2016, 40% of HIV deaths were due to TB).
The mycobacterial cell wall is a highly complex structure largely composed of carbohydrates and
lipids. Major components are lipidated polysaccharides, like the mycolyl−arabinogalactan complex,
essentially composed of galactofuranose (Galf ) and arabinofuranose (Araf ) [205]. In recent years,
numerous efforts have been done to develop inhibitors of UDP-galactopyranose mutase (UGM),
an enzyme essential for the growth and survival of this mycobacterium [206–212]. Among the
vital cell envelope components, phosphatidylinositol mannosides (PIMs) and their corresponding
hyper-mannosylated derivatives (lipomannans and lipoarabinomannans) are noncovalently anchored
to the plasma membrane and the outer capsule via their lipid chains. PIMs have a crucial role in
the intracellular life of the bacterium, by binding to macrophages, to Toll-like receptors and C-type
lectins [213,214], expressed on antigen presenting cell surfaces. PIMs also activate natural killer T
cells for the production of interferon-γ [215]. Structurally, PIMs consist of a myo-inositol moiety
linked with a diacylated glycerophospholipid unit and two α-mannosylation sites at O2 and O6
(Figure 28, compounds 259–261). When additional lipid chains are linked to the mannosyl-and
myo-inositol-moieties, triacylated PIMs (AcPIMs) and tetraacylated PIMs (Ac2PIMs) are formed.
Higher PIMs (for example, AcnPIM3 AcnPIM6) are formed by elongation at the mannose residue.
In the course of the past few years, several synthesis of these structures have been reported [216–221].
In addition, heterocyclic analogues of PIMs in which the inositol ring is replaced by a piperidine or a
tetrahydropyran moiety have been prepared and shown to retain the biological activity of the parent
PIM structures [222].
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Recently, the synthesis of a tetraacylated phosphatidylinositol hexamannoside (Ac2PIM6, 262)
and its immunological evaluation have been reported [223]. Oligomer 262 was synthesized starting
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from pseudotrisaccharide 263, tetramannoside donor 264 and hydrogen phosphonate 265 (Figure 28).
Compounds 263 and 264 were in turn obtained from monosaccharides 266, 267, 268 and 269, 270,
respectively through a [1+1] strategy. The immunological evaluation was performed by observing
the induction of antigen-specific antibodies in mice immunized with ovalbumin or tetanus toxoid
adjuvanted with compound 262. The adjuvant effects of Alum or various PIMs isolated from
M. tuberculosis strain H37Rv (iPIM1,2 and iPIM6) were also examined in parallel for comparison.
Mice exposed to the synthesized Ac2PIM6 262 exhibited increased production of interleukin-4 and
interferon-γ, suggesting proper activation of the innate immune system. Interestingly, 262 induced
an approximately two to four-fold increase in the level of antigen specific antibodies, similarly to
bacteria-derived PIMs and slightly lower than Alum.
Among M. tuberculosis cell wall polysaccharide and lipid components, some complex structures
of arabinogalactan and lipoarabinomannan (LAM) have been synthesized in recent years [224,225].
In particular, Wang et al. [83] synthesized LAM oligosaccharides 271a–273a (Figure 29), that were
conjugated to BSA (271b–273b) and KLH (271c–273c) and evaluated with immunological studies.
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tetrasaccharide coupled to a monophosphoryl lipid A (MPLA), as reported in [226].
LAM tetra-, hepta-, and undecasaccharides 271a–273a, containing the α-1,5-, α-1,3-, and
β-1,2-linked arabinan domain with the 5-OH of the upstream residues capped with the α-1,2-linked
dimannose motif, were synthesized in good overall yields from D-arabinose in 10, 15, and 14 linear
steps, respectively [83]. KLH conjugates 271c–273c and free oligosaccharides 271a–273a were injected
in mice and the obtained antisera were analyzed by ELISA using BSA conjugates 271b–273b as capture
antigens. Antisera derived from mice immunized with oligosaccharides 271a–273a did not contain
carbohydrate antigen-specific antibodies, while all KLH conjugates 271c–273c elicited antigen-specific
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immune responses in mice. In particular, antibody titers induced by 271c and 273c were slightly
higher than those induced by 272c. In a further work [226], the LAM tetrasaccharide was coupled to
a monophosphoryl lipid A (MPLA) derivative generating a MPLA-based synthetic glycoconjugate
274 (Figure 29). In 274, the carbohydrate antigen was attached to the MPLA C-6′-position via an
amide bond. Retrosynthetic analysis of 274 gives LAM tetrasaccharide 275, conveniently synthesized
with a [2+2] strategy from 276 and 277 as reported before by the same authors [83], linker 278, and
MPLA derivative 279. In turn, 279 was synthesized from fatty acids 280 and 281 and disaccharide 282,
assembled from glycosyl donor 283 and acceptor 284. Immunological activity of conjugate 274 was
evaluated in mice, affording robust IgG antibody responses. Since intraperitoneal injection elicited
responses significantly stronger than those from subcutaneous injection, it was hypothesized that
MPLA conjugates may stimulate B1 lymphocytes in the intrapleural and peritoneal cavities. These
results revealed also the self-adjuvant properties of MPLA conjugates, paving the way to further
investigation of these compounds as antituberculosis vaccine candidates.
14. Fungal Infections
Fungal infections can occur in healthy people, although immunosuppressed or
immunocompromised patients are the major risk group for invasive fungal infections, as
well as patients who use antibiotics able to modify the human microbiota [227]. Antifungal drugs
are commercially available but they are limited compared to antibacterial drugs. In recent years,
several strategies have been developed for the identification of new anti-fungal compounds, including
components of plants, animals and microorganism [227]. In particular, vaccination offers promising
alternative solutions for the treatment of fungal infections that are resistant to antibiotics. Recognition
of fungi by the innate immune system depends on several Pathogen-Associated Molecular Patterns
(PAMPs) in the fungal cell wall [228]. Specific receptors, exposed on antigen presenting cells surface,
are involved in the recognition of polysaccharide cell wall components, like the mannose receptor
(MR) and DC-SIGN for recognition of branched N-linked mannan [229], Toll-like receptor 4 (TLR4)
for recognition of linear O-linked mannan [230], galectin 3 for β-mannosides, complement receptor
3 (CR3) for β-(1,6)-glucan, and dectin 1 and TLR2 for β-glucan and phospholipomannan [231].
Mannans consist of differently linked oligomannoside, and phospholipomannans are composed of
phospholipids and mannans. The common linkages between mannose units in fungal mannans are
α-(1,6), α-(1,2)-, α-(1,3) and β-(1,2), as shown in Figure 30. β-glucans are composed of β-D-glucose
with β-(1,3) linkages and sporadic β-(1,6) branched points. Galactomannans consist of structurally
diverse heteropolysaccharides composed of a poly-D-mannose backbone linked to galactofuranoside
(Galf ) units (Figure 30). Of note, the galactomannan of Aspergillus fumigatus is a specific carbohydrate
antigen used for clinical detection of fungal infection.
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In the course of the past few years, several synthetic strategies [232–234] have been developed to
prepare these oligosaccharides expressed on the cell wall of various fungi, like Candida albicans and
Apergillus fumigatus, as detailed in Sections 14.1 and 14.2.
14.1. Candida albicans
The yeast Candida albicans is an opportunistic pathogenic microorganism, found in the
normal microflora, skin and the mucosal surfaces of most healthy individuals. However, it is
able to cause severe infections in immunocompromised individuals and patients undergoing
immunosuppressive therapy [235]. The three major glycans expressed on the cell wall of C. albicans are
phosphomannan-based glycoproteins in the outermost part of the cell wall and β-glucans and chitin,
especially at the level of the bud scars (Figure 31) [228].
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P
Figure 31. Major components of C. Albicans cell wall: β-(1,3)-glucan and chitin
(poly-β-(1,4)-N-acetylglucosamine) are the main components of inner cell wall. The outer
layer is enriched with polymannans.
Being part of the phosphomannan glycoproteins, the acid-labile β-mannan is thought to be a
major epitope of all C. Albicans serotypes and thus represents an ideal target for vaccine development.
On this subject, an extensive work has been carried out by the Bundle group to develop a conjugate
vaccine against C. albicans, starting from binding studies of β-mannans with two monoclonal protective
antibodies, the mAb C3.1 and its immunoglobulin M (IgM) counterpart B6.1 [236]. By means of
STD-NMR, computational analysis [237] and hydroxyl group replacement [238], the identification of
key recognition elements was used for the development of antigens that elicit polyclonal protective
antibodies, a process referred to as “reverse engineering” [236]. Initially, a set of β-(1-2)-mannan
oligosaccharide propyl glycosides 285a–290a (Figure 32) ranging in size from di-to heptasaccharides
were evaluated against mAbs C3.1 and B6.1. Interestingly, di and trisaccharides 285a and 286a had
maximum binding capacity, while larger oligosaccharides were bound progressively more weakly [239].
This unusual pattern of inhibition was consistent with a binding site that could accommodate the
trisaccharide, even though the primary polar contacts are located within the disaccharide. The synthesis
of complementary mono-deoxy and mono-O-methyl analogues of dimers 285b, 291b–304b and trimers
286b and 305b (Figure 32) led to epitope mapping of anti-Candida albicans antibodies [240]. The strategy
for the construction of these β-mannosides is based on the formation of β-glucosidic linkages, followed
by epimerization at C-2 via an oxidation−reduction sequence.
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Dimer 285c and trimer 286c (R = (CH2)3S(CH2)2NH2) were conjugated to chicken serum albumin
(CSA) and the resulting glycoconjugates 285d and 286d (Figure 32) were able to generate highly
specific IgG Abs titers in mice and rabbit [241]. The trisaccharide conjugated to CSA (286d) raised
protective antibodies in rabbits [242]. Serum from rabbits immunized by 286d contained antibodies
that stained C. albicans cells in fluorescent labeling studies more intensely than antibodies from rabbits
immunized with 285d [105,241]. Both glycoconjugates 285d and 286d reduced C. albicans counts in
vital organs but they were insufficient to provide 100% protection. In a further work, trisaccharide–TT
conjugate 286e was found to be a stronger immunogen in rabbits, but it was poorly immunogenic in
mice [241]. However, when the same trisaccharide was conjugated to different T cell peptides, found
in cell wall proteins expressed during pathogenesis of human candidiasis, the resulting glycopeptides
(286f) elicited a peptide- and carbohydrate-specific response that gave protection against challenge by
C. albicans infection in mouse models [243]. All glycoconjugates showed immunogenicity with higher
Abs titers compared to unconjugated 286c. When hyphal wall protein-1 (Hwp1), fructose-bisphosphate
aldolase (Fba) and methyltetrahydropteroyltriglutamate (Met6) were used as T cell peptides for
conjugation, the survival rate in mice challenge experiments was 80–100% against 40–80% survival
with other glycopeptides.
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The C. albica s cell wall consists of approximately 60% β-glucan. Al ough initially thought to be
hidden underneath the mannoprotein layer, recent evidence suggest that β-glucans are exposed on the
cell surface, possibly restricted to specific regions, such as bud scars [228]. β-glucans have also been
investigated for their binding capacity to dectin-1 [244,245], a dendritic cell receptor that mediates
phagocytosis and mediator production during inflammation caused by fungal pathogens [231]. Among
β-glucans, Laminarin (Lam) is a polysaccharide extracted from Laminaria digitate plant. In 2010,
Bromuro et al. [246] investigated the potential of laminarin as antigen for C. albicans, aimed at mediating
antifungal protection. The authors showed that a synthetic linear structure composed of pentadecamer
of Lam β-(1-3) repeating units (15mer) conjugat d to CRM197 co ferred protection agai st C. albicans.
In the same study, a synthetic β-(1-6) branched 17mer conjugated to CRM197 was immunogenic but not
protective [246], suggesting that the linear β-(1-3) fragment contains the protective epitope. To further
investigate this aspect, Adamo et al. [247] reported the synthesis of short linear and β-(1-6) branched
Lam fragments 306a–309a (Figure 33) and their immunological evaluation.
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Compounds 306a–315a were synthesized starting from common building blocks 310, 311, 312
and 313 (Figure 33). Preliminary ELISA test with fragments 306a–309a showed that compound 309a
was the best inhibitor of the binding between Lam and anti-Lam Abs elicited in mice by Lam-CRM197
conjugate, confirming the hypothesis that the linear β-(1-3) fragments contain the dominant epitope.
Hexasaccharide 314b, prepared from building block 315 (Figure 33), was studied in order to identify the
protective epitope. ELISA assays on compounds 306a–309a and 314b showed that hexasaccharide 314b
provided 95% of inhibition at 4 mM concentration, while trisaccharide 309a and tetrasaccharide 307a
provided 85% and 73% of inhibition at the same concentration, respectively. Based on these results,
compound 314b was conjugated to CRM197 and employed for mice immunization. Sera analysis
showed that glycoconjugate 314c was able to induce specific anti-Lam IgG Abs titers significantly
higher and homogeneous compared to Lam-CRM197 conjugate. This result suggested that the linear
hexasaccharide β-(1-3) glucan 314b is long enough to cover the dominant epitope of C. albicans.
In 2015, Liao et al. [248] reported the synthesis of longer β-(1-3) glucan chains such as fragments
316a–319a (Figure 34). Hexasaccharide 316a was assembled with a [4+2] glycosylation reaction
from donor 320 and compound 321 after cleavage of 2-Naphthylmethyl ether (Nap) group. Longer
oligomers 317a, 318a and 319a were obtained via [4+4] (from 320), [8+2] (from 322 and 321) and
[8+4] (from 322 and 320) glycosylation strategies, respectively (Figure 34). Oligomers 316a–319a were
conjugated to KLH and KLH conjugates (316b–319b) were injected in mice, raising high IgG1 titers
with significant statistical difference between hexasaccharide 316b and longer oligomers 317b–319b.
Octasaccharide 317b resulted the most immunogenic and protective compared to decasaccharide
318b and dodecasaccharide 319b. This result encouraged the authors to perform fungal challenge
experiment in mice with glycoconjugate 317b using C. albicans fungus strain SC5314. In this experiment,
11 mice were immunized with 317b and, after challenge, 4 mice (about 34%) were unaffected,
suggesting their protection from C. albicans.
More recently, Liao et al. [249] reported similar immunological studies of fragments 323a–325a
containing the dominant linear octasaccharide and β-(1-6) and β-(1-3) branches with different chain
length (Figure 35). KLH conjugates 323b and 324b were more immunogenic than 325b but the majority
of elicited Abs were against the common β-glucan motif. In addition, conjugates 323b and 325b
confer similar long-term protection against C. albicans infection (survival rate about 37%, 30 days after
challenge for both conjugates). These data confirmed the hypothesis that linear β-(1-3) glucans of
6–8 units without branches can cover the dominant epitope of C. albicans.
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14.2. spergillus fumigatus
Aspergillus fumigatus causes severe and usually fatal invasive aspergillosis infections in
i unosuppressed hospitalized patients. ore than 90 of the cell all of A. fumigatus co prises
polysaccharides, a ong hich α-(1,3)-glucan is present in percentages variable fro 20 to 40 . This
virulence factor suffers of poor solubility in ater, aking difficult the study of its i unological
properties. The use of shorter synthetic frag ents could overco e the solubility issue. Indeed,
Ko arova et al. [250] reported the synthesis of pentasaccharide fragment 326a (Figure 36),
the BSA-glycoconjugate (326b) and its evaluation as a vaccine candidate. Pentasaccharide 326a
was prepared via a [3+2] glycosylation between donor 327 and acceptor 328. These protected
fragments were in turn synthesized from monomers 329 and 330. The use of benzoyl group at
6-OH as remote partecipating group during glycosylation reactions facilitated the formation of
α-linkages. Glycoconjugate 326b was immunized in mice, eliciting highly specific and protective
polyclonal antibodies.
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Gala tomannan is a specific polysaccharide pr d ced by A. fumigatus composed of a linear
mannan core partially branc ed with β-(1,5)-galactofuranoside (Galf ) units via β-(1,6) or β-(1,3)
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linkages (Figure 37) [251]. The length of β-(1,5)-Galf branches differs among different cultures, making
difficult the identification of a common repeating unit for galactomannans. Recently, Kudoh et al. [252]
demonstrated the presence of significant structural differences in both the O-linked and N-linked
oligosaccharide of A. fumigatus galactomannans, depending on growth conditions in different culture
media. Moreover, the authors revealed new structural elements of A. fumigatus galactomannan, the like
the presence of β-(1,6)-linked Galf residues in addition to the β-(1,5)-linked Galf residues (Figure 37).
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Figure 37. A. fumigatus galactomannan structure, underlining the presence of β-(1,6)-linked Galf
residues in addition to the β-(1,5)-linked Galf residues, as reported in [252].
The galactofuranosides (Galf ) are not presents in mammalian cells and they are therefore used for
diagnosis of human infections. In addition, they can be advantageously used as antigen candidates for
an anti A. fumigatus vaccine.
Recently, the Nifantiev group reported the synthesis of pentasaccharide fragments of the
galactomannan containing the β-(1,5)-linked galactofuranoside chain attached to O-3 or O-6 of a
mannopyranoside residue (GM-1 331a, GM-2 332a and GM-3 333a) [253] and fragments 334a–343a
(Figure 38) [254]. In particular, pentasaccharide 331a was achieved via [2+3] glycosylation between
disaccharide donor 344 and trisaccharide acceptor 345 (Figure 38), in turn prepared from donor 344
and mannosyl acceptor 346. Disaccharide 344 was synthesized from monosaccharides 347 and 348,
both derived from allyl galactoside 350 through furanoside 349 (Figure 38).
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The authors showed [255] that two mAbs (7B8 and 8G4), recognizing galactomannan in
A. fumigatus, were elicited in mice after immunization with glycoconjugate 331b. Glycoarray analysis
performed with synthetic biotinylated oligosaccharides 331c–343c and mAbs 7B8 and 8G4 showed high
affinity towards pentasaccharide 331c and heptasaccharide 343c while no recognition was observed
for mono- and disaccharides 334c–338c. Finally, confocal microscopy was used to evaluate the
binding between the two mAbs and A. fumigatus and a series of other fungi and bacteria. mAbs
7B8 and 8G4 were selective for A. fumigatus, suggesting that they can be used as reagents for immune
diagnostics. Recent advances in galactofuranoside synthesis [205,232,233] should facilitate the access
to galactomannan fragments, thus opening the way to anti A. fumigatus vaccines based on synthetic
Galf oligomers.
15. Conclusions
Pathogen surface glycans are promising vaccine targets due to their crucial role in adhesion
to host tissues. Firstly, pathogen polysaccharides act as a protection barrier either by delaying the
host’s immune response or by mimicking the host self-glycans. They are therefore essential for the
survival of microorganisms in the blood and play a major role in their virulence. Secondly, most
glycans are recognized by antigen presenting cells and triggers the innate immune response, starting
the inflammatory process and eventually the antigen-specific adaptive immunity. Based on these
considerations, the highly conserved polysaccharides (PS) exposed on pathogens cells surface are
important virulence factors and have been used as antigens for vaccines development in a range of
infectious diseases, including meningitis, pneumonia, otitis media, sepsis, infectious diarrheas, etc...
The first-generation polysaccharide vaccines made of purified T cell-independent polysaccharide
antigens have limited efficacy in infants, in the elderly and immunocompromised individuals and,
in general, they don’t result in B cell-mediated immunological memory. The second-generation
polysaccharide vaccines consist of native PS, produced and purified from natural sources and
chemically conjugated to immunogenic carrier proteins able to elicit a T cell-dependent immune
response (glycoconjugate vaccines). The purified native PS displays heterogeneity of chain length
and may contain copurified endotoxin or other polysaccharides, introducing complications into
the manufacturing process. Recent advances in carbohydrate chemistry has opened the way to a
third-generation of polysaccharide vaccines, based on the use of synthetic oligosaccharides conjugated
to carrier protein. The breakthrough in synthetic vaccines was carried out for H. influenzae type b
in 2004, when the Vérez Bencomo research team in Cuba synthesized the first synthetic conjugate
vaccine currently available under the trade name Quimi-Hib [9–62]. This approach is based on the
hypothesis that protein conjugates of synthetic oligosaccharide fragments, smaller than the native PS,
can elicit PS-specific and protective antibodies. The main challenge for the development of effective
glycoconjugate vaccines is the determination of the carbohydrate antigen chain length and the sequence
of the minimal protective immunogenic fragment of the antigen, a process often referred to as epitope
mapping. The optimal carbohydrate antigen chain length needed for inclusion in a glycoconjugate
vaccine, for example, cannot be predicted a priori for any given bacterial species. Despite the old
paradigm established by Kabat [256], stating that immunogenic glycan epitopes usually comprise
structures not longer than six-eight sugar units, the effect of the carbohydrate chain length on the
immunogenicity of the corresponding protein conjugate is strictly case-dependent. There are many
reported cases where both long chain glycans and oligosaccharides as short as tetrasaccharides have
been shown to possess the minimal structural requirements for raising protective immunity, and several
examples are illustrated throughout this review. In this regard, synthetic chemistry is a formidable tool
to define the role of this crucial parameter, and more generally speaking of each structural variable
affecting the immunogenicity and efficacy of vaccine candidates. Over the last years, much progress
has been made. The rational design of carbohydrate antigens and the use of increasingly sophisticated
synthetic strategies has made the preparation of even highly complex microbial glycans possible.
In addition, the application of modern site-selective protein conjugation strategies [6,257,258] (a subject
Molecules 2018, 23, 1712 39 of 52
not addressed in the present review), has enabled the preparation of chemically defined glycoconjugate
vaccine candidates featured by robust structure-immunogenicity relationship, which are expected to
display improved safety and efficacy profiles [259]. These new achievements have certainly opened up
new perspectives and hope for the prevention of severe bacterial and fungal infections still affecting
the pediatric population worldwide. We truly wish that these promising results translate into new and
efficient vaccines in the next few years.
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